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Abstract
M. ELIZABETH G. BURTON. Regulation of VCAM-1 expression by TGFt32 during
formation of the epicardium. (Under the direction of STEVEN W. KUBALAK, Ph.D.)
The normal formation of the epicardium, the outer cel/layer of the heart, is critical for
subsequent development of the heart to proceed normally. Abnormalities in the epicardium lead
to cardiac defects as shown in mice deficient in retinoid X receptor a (RXRa-/-), a model of
congenital heart disease that exhibits many cardiac malformations including epicardial defects.
The RXRa-/- epicardium is slower to form and once formed, it detaches from the myocardium.
Previously an elevation of transforming growth factor

~2

(TGFf32) has been observed in RXRa-/-

hearts at midgestation and an alteration in vascular cell adhesion molecule 1 (VCAM-1) was
found at E11.5. Based on these findings it was hypothesized that proper expression of VCAM-1
is essential for normal cardiac morphogenesis and is regulated by TGF~2 and/or retinoid
signaling. VCAM-1 is a transmembrane protein known to be involved in epicardial cell adhesion
and has been reported to inhibit epithelial to mesenchymal transformation (EMT) of epicardial
cells. In this study the expression of VCAM-1 was analyzed from E9.5-E13.5 in the wild type

(WT) and RXRa-/- mice using real time quantitative PCR, immunohistochemistry and western
blotting. At E11.S, VCAM-1 protein expression levels were similar to WT in the RXRa-/- mouse,
but later (E12.S and E13.S) misexpression of VCAM-1 was found in the epicardium of RXRa-/mice. Specifically, VCAM-1 mRNA and protein were increased in the myocardium of the RXRa/- heart compared to the WT at E12.S and E13.5. Elevation ofVCAM-1 protein was also found
in E13.5 epicardial explants from RXRu-/- embryos. To investigate possible involvement of

TGFB2 in VCAM-1 regulation, E11.5 epicardial explants were treated with

TGF~2

and the

treatment was found to promote upregulation of VCAM-1 in the epicardial cells. Treatment of
embryos in whole embryo culture with

TGF~2

resulted in elevation of VCAM-1 and also caused

xi

epicardial detachment after 18 hours of treatment. RXRa and Smad4 were shown to bind to the
mouse VCAM-1 promoter using ChiP analysis and the VCAM-1 promoter can be activated by
TGF~2

treatment (shown through use of a luciferase expression plasmid containing the VCAM-

1 promoter). Together the findings show that VCAM-1 is elevated in the hearts of RXRa-/- mice
and

TGF~2

can regulate VCAM-1 expression in the embryonic heart, particularly in the

epicardium. Elevated

TGF~2

in the heart, such as that observed in the RXRa-/- mouse, can

cause upregulation of VCAM-1 in the myocardium and epicardium. Upregulation of VCAM-1
could decrease epicardial EMT, which is also observed in the RXRa. From our study we show
that proper expression (levels and location) of VCAM-1 is essential for normal heart
development and that misexpression of VCAM-1 can negatively affect formation of the heart.

xii

Chapter 1: Review of Literature

A. Congenital Heart Disease
Congenital heart defects (CHDs) are the most common birth defect, affecting
approximately 1% of all live births. Presently, treatment of CHDs is limited to surgical
and pharmaceutical intervention. Major CHDs are usually seen during the neonate
period while some minor CHDs may not be found until adulthood making the prevalence
of CHD likely much higher than reported. Currently there are few options to reduce the
occurrence of CHD. Taking prenatal vitamins has been shown to reduce the occurrence
as well as avoiding environmental exposure to risky medications, chemicals and certain
illnesses (Jenkins et aI., 2007). Even with these precautions, CHDs are quite prevalent
so other interventions are necessary to prevent their occurrence.
Retinoid signaling is known to playa role in the development of the heart with too
much or too little signaling resulting in heart defects. The effects of retinoid signaling on
the developing heart have been shown in models such as that of the vitamin A
deficiency (VAD) rat (Wilson and Warkany, 1949) and human birth defects that result
from exposure to the drug Accutane (isotretinoin- Roche), a retinoid receptor ligand (de
la Cruz et aI., 1984). The retinoic acid synthesizing enzyme retinaldehyde
dehydrogenase 2 (RALDH2) is expressed in the epicardium of the heart indicating that
retinoid signaling is important within the epicardium. In the mouse, loss of the retinoid X
receptor alpha (RXRu) results in embryos displaying defects in all regions of the
developing heart. Specifically, the RXRa-/- embryo displays hypoplastic endocardial
cushions, thinning of the ventricular myocardium and detachment of the epicardium.

1

Dysfunction of the epicardium could cause common congenital abnormalities that are
seen throughout the heart in the human population including coronary artery anomalies,
septal and valve defects. Currently there are no reported epicardial-specific defects
(loss of epicardium or bubbling of the epicardium) in the human congenital heart defect
population. There are, however, rare reports of congenital absence of the pericardium
(structure derived from the epicardium) (Abbas et aI., 2005).

B. Cardiac Morphogenesis

The heart is derived from cardiac progenitor cells that are found in the epiblast of
the developing embryo (Martinsen, 2005). These cardiac progenitor cells form the
bilateral primary heart field and the secondary heart field (Buckingham et aI., 2005;
Cohen-Gould and Mikawa, 1996; Garcia-Martinez and Schoenwolf, 1993; Martinsen,
2005). The primary heart field is located on either side of the primitive streak forming
two separate but paired regions (the cardiac crescent) (Dyer and Kirby, 2009; Martinsen,
2005) (Figure 1-A). The two sides of the cardiac crescent will form endocardial heart
tubes and migrate to the midline to form the primary heart tube, which will begin to beat
(Martinsen, 2005) (Figure 1-B). The primary heart tube consists of an inner layer of
epithelial endoderm, an outer layer of myocardium with an extracellular matrix (ECM)rich cardiac jelly between the two layers (Markwald et aI., 1977; Smith and Bader, 2007).
The secondary heart field is located anterior and dorsal to the primary heart tube and will
form the right ventricle, outflow tract and venous poles (Buckingham et aI., 2005; Kelly et
aI., 2001; Mjaatvedt et aI., 2001; Srivastava, 2006; Verzi et aI., 2005; Waldo et aI., 2001;
Zaffran et a/., 2004) (Figure 1-A). After the primary heart tube is completely fused, it will
rightwardly loop to form the atria, atrioventricular junction and left ventricle (Manner,
2000; Snarr et aL, 2008; Srivastava, 2006) (Figure 1-C). Once looping is complete, the
chambers of the heart will begin to remodel and septate to form the four-chambered
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Figure 1: Heart Development. The heart initially forms as a cardiac crescent around Day
15 of human development (E7.5 of mouse development) and consists of the first
(primary) heart field (red) and the second heart field (blue) (A). The crescent will fuse
the midline of the embryo to form the heart tube around Day 20 of human development
(E8 of mouse development) (8). The heart will then loop rightward around Day 28 of
human development and E9 of mouse development (C). Starting at Day 32 (mouse
E1 0), the heart will further remodel to form the mature four chambered heart (D). FHF,
first (primary) heart field; SHF, second heart field; RV, right ventricle; LV, left ventricle;
RA, right atrium; LA, left atrium; V, ventricle; aT, outflow tract. Adapted from: (Bruneau,
2008)
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heart (Figure 1-0). The complete four-chambered heart is made up of the primary heart
field and the secondary heart field as well as from contributions from neural crest cells
and epicardially-derived cells. The primary heart field contributes to the atria,
atrioventricular junction and the left ventricle (Buckingham et aI., 2005). The second
heart field will form the outflow tract, right ventricle and parts of the venous pole
(Buckingham et aI., 2005).
During looping, some of the endocardial cells overlying the cardiac jelly will
delaminate, migrate into the cardiac jelly and eventually form the endocardial cushions
(Markwald et a!., 1977; Potts et aI., 1991). The endocardial cushions appear as
localized swellings of the cardiac jelly in the atrioventricular junction and the outflow tract
and contain extracellular matrix molecules and eventually mesenchymal cells of varying
origins (Schroeder et aI., 2003; Snarr et aI., 2008). Part of the ventricular septum, the
outflow tract septum and the valves are, in part, derived from the endocardial cushions
(Eisenberg and Markwald, 1995). Neural crest cells will migrate into the developing
heart and contribute to the development of the outflow tract septum, semilunar valves,
the great arteries and sympathetic innervation of the heart (Hildreth et aI., 2008; Hutson
and Kirby, 2007; Nakamura et aI., 2006; Verberne et aI., 1998). The epicardium will
form from cells derived from the proepicardium and cover the myocardium (Viragh and
Challice, 1981) (Figure 2). Some cells from the epicardium will undergo epithelial to
mesenchymal transformation (EMT) to contribute to various processes and structures in
the heart including the maturation and development of the myocardium, seeding of the
endocardial cushions and become endothelial and smooth muscle cells of the coronary
vasculature (Dettman et aI., 1998; Manner, 1999; Mikawa and Fischman, 1992; PerezPomares et aI., 2002; Perez-Pomares et aI., 1998).
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Figure 2: Illustration of epicardium formation in the E9.S mouse. The inset shows the
relationship between the proepicardium and the myocardium during the early stages of
epicardium formation. The asterisk indicates an area where proepicardial cells are
directly interacting with the myocardium. The black arrow indicates an area of
myocardium that is covered by newly formed epicardium. The red arrow indicates an
area of bare myocardium.
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c. Formation of the epicardium
The epicardium is an important structure in the heart because it contributes cells
and signals to aid in the formation of many structures in the developing heart. Loss of
the epicardium or proper epicardium function results in various heart defects including
defective development of coronary vasculature and abnormal ventricular chamber
development. The epicardium, the epithelial covering of the myocardium, is derived
from a cell population referred to as the proepicardium (PE) (Manasek, 1969; Viragh and
Challice, 1981) (Figure 2). The PE is a cluster of cells of mesenchymal and epithelial
origin contained within an extracellular matrix (ECM) (Viragh and Challice, 1981). It is
located on the septum transversum above the liver primordium and will form from the
pericardial coelomic mesothelium (Manner, 1992; Schulte et aI., 2007; Tomanek, 2005;
Viragh and Challice, 1981) (Figure 2). The PE contains precursors for endothelial,
smooth muscle and connective tissue cells (Mikawa and Gourdie, 1996).
During the transition from PE to epicardium, which occurs between embryonic
day (E) 9.0 and E10.0 (looping of the heart) in the mouse, cells from the PE will
delaminate and form vesicular-like buds (Manner et aI., 2001; Mikawa and Gourdie,
1996; Viragh and Challice, 1981; Viragh et aI., 1993) (Figure 2). These buds will migrate
to the myocardium where they will attach and move across the surface of the
myocardium, proliferate and form the epicardium (Komiyama et aI., 1987; Viragh and
Challice, 1981) (Figure 2). The extracellular matrix within the proepicardial buds will
become part of the subepicardial space, which contains fibronectin, collagens I, IV, V
and VI (Bouchey et aI., 1996; Hurle et aI., 1994; Kalman et aI., 1995; Kim et aI., 1999;
Tidball, 1992), proteoglycans, laminin (Kalman et aI., 1995) vitronectin, fibrillin-2 and
elastin (Bouchey et aI., 1996). These ECM proteins play roles in epicardium attachment,
coronary vasculogenesis and possibly other roles such as signaling to the myocardium
from the epicardium. Mesenchymal cells, derived from the proepicardial buds or from
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the newly formed epicardium, will also occupy the subepicardial space and form
epicardially-derived cells (EPDCs) (Dettman et aI., 1998; Munoz-Chapuli and Hamlett,
1996; Munoz-Chapuli et aI., 1994; Perez-Pomares et aI., 1997, 1998; Van den Eijnde et
aI., 1995; Viragh et aI., 1993).
The PE cells can reach the myocardium in one of two ways depending on
species. In the mouse and other mammals, the PE buds will free-float through the
pericardial space to the myocardium; however there is also some direct migration that
will occur (Komiyama et aI., 1987; Kuhn and Liebherr, 1988; Munoz-Chapuli et aI.,
1994). In the chick there is evidence that the PE buds migrate to the myocardium via an
extracellular matrix bridge made up of fibronectin, glycoproteins and collagens (Manner
et aI., 2001; Nahirney et aI., 2003). It has been hypothesized that mice also have this
extracellular matrix bridge but this has not been shown. A recent report in mouse
suggests that the PE will form microvili that will protrude and attach to the myocardium
as the main method by which PE cells reach the myocardium but that some PE budding
does occur (Rodgers et aI., 2008).
Epicardial cells with undergo EMT to form EPDCs that will contribute to interstitial
fibroblasts, seeding of the endocardial cushions, fibroblasts of the endocardial cushions
and smooth muscle cells and endothelial cells of the coronary vasculature (Dettman et
aI., 1998; Gittenberger-de Groot et aI., 1998; Manner, 1999, 2000; Mikawa and
Fischman, 1992; Mikawa and Gourdie, 1996; Perez-Pomares et aI., 1997; Vrancken
Peeters et aI., 1999). The epicardium normally expresses RALDH2, a retinoic acid
synthesizing enzyme (Duester, 2000) and Wilms' tumor 1 transcription factor (Wt1)
(Little et aI., 1999). As EPDCs develop into smooth muscle and endothelial cells of the
coronary vasculature, RALDH2 and Wt1 will be downregulated within the cells (PerezPomares et a/., 2002). Wt1 has previously been implicated in epicardium development
with loss of Wt1 causing a failure of epicardium formation (Moore et aI., 1999).
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Two recent ere-models have suggested that EPDCs will also become myocytes
in the ventricular myocardium and interventricular septum (Cai et aI., 2008; Zhou et aI.,
2008a; Zhou et aI., 2008b). A Wt1 GFPcre/+ mouse was used to trace the fate of Wt1 +
epicardial cells throughout the heart (Zhou et aI., 2008a). Some of these Wt1 + cells
differentiated into functional cardiomyocytes that were found in all four chambers of the
heart as well as in the interventricular septum (Zhou et aI., 2008a). These Wt1expressing cardiomyocytes also expressed GATA4 and Nkx2-5 (Zhou et aI., 2008a).
Wt1 + PE cells were found to arise from Nkx2-5 and 151et1 (lsl1 )-expressing progenitor
cells, indicating that PE/epicardial cells may share a developmental origin from
cardiogenic progenitor cells (Chien et aI., 2008; Laugwitz et aI., 2008; Martin-Puig et aI.,
2008; Zhou et aI., 2008a). A Tbx18-cre has also been used to label epicardial cells and
trace EPOCs in the developing heart (Cai et aI., 2008). Cai et al found that Tbx18+
epicardial cells went to the interventricular septum and the ventricular myocardium
where they became cardiomyocytes that were Nkx2-5+ (Cai et aI., 2008). These data
(Cai et aI., 2008) support the findings of Zhou et al. However, there has been some
debate from another group who suggests that Tbx18 is normally expressed in the
interventricular septum and myocardium and is found in a mouse model with absent
epicardium and therefore cannot be used as a marker of epicardially-derived
cardiomyocytes (Christoffels et aI., 2009). Further evidence supports the theory that
PE/epicardial cells are derived from the same cardiogenic progenitor pool as
cardiomyocytes in work from van Wijk et al. This group found through Oil tracing that
PE/epicardial cells come from the same precursor pool as the inflow myocardium and
that this separation of PE/epicardium from myocardium required a balance of BMP and
FGF signaling (van Wijk et aI., 2009). FGF2 was found to enhance epicardium formation
while BMP stimulation enhanced myocardium formation (van Wijk et aI., 2009). These
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recent studies of EPDC cells fate suggest a new role for EPDCs as a cardiomyocyte
progenitor cell population.
Cell-cell as well as cell-matrix interactions are necessary for proper epicardial
EMT. For example, connexin-43, vascular cell adhesion molecule (VCAM-1) and
integrin a4 have been previously noted to be required for epicardial EMT (Kwee et aI.,
1995; Li et aI., 2002; Rhee et aI., 2009; Yang et aI., 1995). Loss of Cx43, a gap
junctional protein, in the mouse results in embryos with decreased epicardial EMT as
well as bubbling of the epicardium (Rhee et aI., 2009). Loss of VCAM-1 or integrin a4 in
the mouse results in embryos that have no epicardium, thus, form no EPDCs (Kwee et
aI., 1995; Yang et aI., 1995). Erythropoietin (EPO) and retinoic acid are produced by the
epicardium and are thought to signal for secretion of trophic signals that aid in
myocardium development (Chen et aI., 2002; Perez-Pomares et aI., 2002; Stuckmann et
al.,2003). EPO knockout mice have been previously reported to have a detached
epicardium similar to the RXRa-/- mouse (Wu et aI., 1999). Failure to properly signal to
the myocardium from the epicardium can affect myocardium development as both the
EPO knockout and RXRa-/- have hypoplastic ventricles indicating the importance of
proper epicardium function. It may be that detachment of the epicardium impairs proper
functioning of the epicardium. Currently, the mechanism by which the epicardium can
become detached and the role this detachment plays in epicardial signaling and EMT is
not fully known.

D. Mouse models of aberrant epicardium formation
Since defects in the epicardium lead to various abnormalities in the heart
including hypoplastic ventricular myocardium and coronary vasculature anomolies,
animal models that perturb proteins and molecules important for epicardium
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development result in many of these phenotypes. A list of these mouse models is found
in Table 1. Integrin a4 is a celt surface receptor that is involved in cell-cell and cellmatrix interactions (Hynes, 1992) and is expressed in the epicardium. Knockout of
integrin a4 results in two possible phenotypes. The first phenotype is failure of allantois
fusion early in development affecting extraembryonic circulation leading to embryonic
lethality by E11 (Pineo et aI., 2001; Yang et aI., 1995). Other embryos fail to form an
epicardium and have hypoplastic ventricular myocardium and missing coronary
vasculature resulting in embryonic lethality by E14.5 (Pineo et aI., 2001; Yang et aI.,
1995) (Figure 3). Integrin a4 promotes migration of proepicardial cells over the surface
of the myocardium through its interaction with VCAM-1 on the surface of the
myocardium. Proepicardial cells come into contact with the myocardium but will not
migrate over the surface of the heart in the absence of integrin a4 in a4-knockin-lacZ
mice (Sengbusch et aI., 2002). In the absence of integrin a4 in this mouse model, there
is also decreased proepicardial cell budding, indicating a role for integrin a4 in
proepicardial cell bud formation to initiate migration over the myocardium (Sengbusch et
aI., 2002). Integrin a4 will interact with fibronectin during proepicardial cell budding and
with fibronectin and/or VCAM-1 during proepicardial cell migration over the myocardial
surface to aid in formation of the epicardium (Sengbusch et aI., 2002). Loss of the ability
of PE cells to bind to the myocardium via an interaction between integrin a4 and VCAM1 can result in failure to form an epicardium.
VCAM-1 is a cell surface protein and a ligand for integrin a4 that is involved in
inflammatory processes and development (Kwee et al. , 1995) and is expressed within
the myocardium. VCAM-1 knockout mice (VCAM-1-/-) are embryonic lethal and die
between E1 0.5 and E12.5 with two different phenotypes (Kwee et aL, 1995). One group
of embryos did not develop extraembryonic circulation while the other group of embryos
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Table 1: Knockout mice displaying an epicardial phenotype.
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KO mice with Epicardium
Detachment
RXRa
Epicardial-specific ALK5
Cx43
N-cadherin Wnt-1 Cre conditional KO
EPO/EPO receptor
Podoplanin
Foxc1/c2

14

KO mice with Epicardial
Defects
VCAM-1
Integrin a4
Wt1
GATA4
PAR3

Figure 3: Epicardial phenotype of the integrin a4 knockout mouse. A histological
analysis of the integrin a4 knockout from E1 0.5 to E12.S. WT at E12.5 (A,e) has an
epicardium present. KO at E12.S (B,O) has no epicardium present. KO at E10.5 (E)
has an epicardium present but is lost by E11.5 (F). The
forms coronary vessels (G)
while the KO has none present (H). A, atrium; Ee, endocardial cushions; B, blood cells;
Cv, coronary vessel; Ep, epicardium; M, myocardium; 0, outflow tract; V, ventricle
(Taken from Yang et ai, 1995)
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16

Figure 4: Epicardial phenotype of the VCAM-1 knockout mouse. The wr mouse at
E11.5 (A-C) forms a epicardium (indicated by arrowheads). The KG mouse fails to form
an epicardium by E11.5 (D-F). (Taken from Kwee et ai, 1995)
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showed various heart defects including loss of epicardium hypoplastic ventricular
1

myocardium and abnormal coronary vasculature (Kwee et aI., 1995) (Figure 4). In the
absence of VCAM-1, there is also a loss of integrin a4 expression in the epicardium but
not in the endocardial cushions (Kwee et aI., 1995). VCAM-1-/- mice fail to form an
epicardium by E11.S, however, a small number of epicardial cells can be seen on the
atria (Kwee et aI., 1995). The failure of the epicardium to form could be due to the
inability of the PE buds to attach to the surface of the myocardium in the absence of
VCAM-1. As seen with other models of aberrant epicardial development, there is a
reduction in myocardial wall thickness and a decrease in ventricular compaction (Kwee
et aI., 1995) (Figure 4). The phenotype of VCAM-1-/- is similar to that of integrin a4-/-,
which could be expected considering the two proteins are binding partners and likely
involved in the same developmental processes during heart formation. VCAM-1 is
expressed in the myocardium while integrin a4 is expressed in the epicardium,
suggesting a role for each in adhesion between the epicardium and myocardium (Kwee
et aI., 1995; Yang et aI., 1995). Alterations in the levels of either VCAM-1 or integrin a4
could have adverse effects on intercellular binding between these proteins potentially
due to changes in the stoichiometry of these transmembrane proteins.
N-cadherin has been implicated in proper epicardial attachment. Conditional
knockout (eKO) of N-cadherin specifically in the neural crest cells caused an epicardial
bubbling phenotype similar to that of the RXRu-/- mouse (Luo et al., 2006) (Figure 5). It
was found that Wnt1-Cre used for the conditional knockout is also active in epicardial
cells resulting in decreased N-cadherin in the epicardium as well (Luo et aI., 2006). In
these mice, the epicardium itself remains intact but is detached from the underlying
myocardium. N-cadherin is normally expressed in both the myocardium and epicardium
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Figure 5: Epicardial phenotype of the N-cadherin conditional knockout mouse. The
mouse forms at normal attached epicardium seen in H&E stained sections (A,C) and
whole mount (E). The CKO mouse forms a detached epicardium seen in H&E stained
sections (8,0) and whole mount (F- arrow indicates detached epicardium).
Immunofluorescence for N-cadherin shows it present in the epicardium of the wr (arrow
in G) and absent in the eKO (arrow in H). Epicardial explants showed N-cadherin
present in the WT (I) and present at low levels in the eKO (J). (Taken from Luo at ai,
2006)

20

21

and is involved in adhesion of the epicardium to the myocardium via formation of
adherens junctions (Luo et ai" 2006). In addition to the detached epicardium, there is
also thinning of the ventricular myocardium similar to what is seen in other mice that
have epicardial defects (Figure 5).
Another mouse model that fails to form an epicardium is the Wilm's Tumor 1
(Wt1) knockout mouse. wt1 is a zinc finger transcription factor that targets genes such
as those responsive to retinoic acid receptors and integrin a4 signaling (Kirschner et al.,
2006; Little et aI., 1999). Wt1 knockout mice have no epicardium, hypoplastic ventricular
myocardium and improper formation of the coronary vasculature (Moore et aI., 1999).
This is similar to the integrin a4 knockout mouse so it is possible that decreased
transcription of integrin a4 due to loss of Wt1 contributes to the phenotype of Wt1
knockout mice further pointing to the importance of integrin a4 and its interactions in
normal epicardium formation. Embryos with an epicardial-specific knockout of Wt1 die
between E16.5 and E18.5 as a result of cardiovascular failure (Martinez-Estrada et aL,
2010). These embryos fail to form coronary vasculature and had an upregulation of Ecadherin and cytokeratin (indicative of epithelial phenotype) and a reduction in the
mesenchymal cell markers Snail and vimentin expression, indicating a reduction of
epicardial EMT (Martinez-Estrada et aI., 2010). Using immortalized epicardial cells with
a tamoxifen-inducible Wt1 knockout, it was found that loss of Wt1 increased E-cadherin
"
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expression, downregulated N-cadherin and decreased cell migration (Martinez-Estrada

i

et aI., 2010), indicating the importance of Wt1 in epicardial EMT.
Podoplanin is a mucin-like transmembrane glycoprotein that has been found to
downregulate E-cadherin in human oral and mouse skin carcinomas leading to an
upregulation of EMT (Mahtab et aI., 2008; Martin-Villar et aI., 2005). Loss of podoplanin
produces embryos that have hypoplastic and perforated ventricular and septal
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myocardium, hypoplastic atrioventricular cushions, epicardial detachment, incomplete
epicardium formation and impaired coronary vasculature formation (Mahtab et aI., 2008).
A reduction in epicardial EMT was also found as a result of upregulation of E-cadherin
(Mahtab et aI., 2008), indicating the importance of the appropriate ratio of cell adhesion
molecules to epicardial EMT.
GATA4 is a zinc finger transcription factor that interacts with other proteins
important for heart development including Nkx2.5 (Watt et aI., 2004). GATA4 knockout
mice have no proepicardium and as a result lack an epicardium and have hypoplastic
ventricular myocardium, disrupted looping and disrupted septation (Watt et aI., 2004),
suggesting a role for GATA4 more in development of the PE.

Friend of GATA 2

(FOG2) is a cofactor for GATA transcription factors (Tomanek, 2005). FOG2 knockout
mice have abnormal epicardial EMT resulting in hypoplastic ventricular myocardium,
common atrioventricular canal and absence of coronary arteries (Tevosian et aI., 2000),
suggesting a role for FOG2 in transcription of genes involved in epicardial EMT.
Foxc1 and Foxc2 are forkhead/Box transcription factors that playa role in the
development of the heart, especially in the formation of the outflow tract (Sea and Kume,
2006). Combination Foxc1 heterozygote and c2 knockout mice have improper formation
and function of the epicardium including detachment from the myocardium, accelerated
EMT, failure of outflow tract septation, hypoplasia of the outflow tract, defects in
endocardial cushions and a thin myocardium (Sea and Kume, 2006). The phenotype of
the Foxc1 +/-/c2-/- mouse is quite similar to the RXRa-/- mouse with the exception of the
accelerated EMT. Transforming growth factor

~-2 (TGF~2)

signaling has previously

been shown to be required for expression of Foxc1 in the eye during development (Ittner
et aI., 2005). Foxc1 has also been shown to be a TGF~1 responsive gene and can be
upregulated by

TGF~1

in several cancers (Zhou et aI., 2002). Foxc2 has been shown
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previously to interact with Smads to promote EMT (Fuxe et aI., 2010). Since both Foxc1
and Foxc2 have been implicated in EMT, it is possible that these two transcription
factors could playa role in EMT in the epicardium, possibly with TGFB2.
PAR3 is a protein that complexes with PAR6 and atypical protein kinase C
(aPKC) to establish epithelial cell polarity and has been shown to be important for
epithelial cysUbud formation (Hirose et aI., 2006; Hurd et aI., 2003; Joberty et aI., 2000).
PE cells express both integrin a4 and GATA4 but fail to form buds to migrate to the
myocardial surface, thereby failing to form an epicardium by E11 ,5 (Hirose et aI., 2006).
There were no integrin a4-positive cells on the surface of the myocardium (indicating
that no epicardial cells were present) but there was no effect on the expression of
VCAM-1 in the myocardium (Hirose et aI., 2006). PAR3 is important for the formation of
epithelial cell junctions with loss of proper cell junctions leading to a loss of PE bud
formation (Hirose et aI., 2006). These results point to the importance of cell adhesion to
the formation of the epicardium.
Erythropoietin (EPO) is a growth factor that is involved in various processes in
the body such as endothelial cell proliferation and erythrocyte production and in heart
development (Anagnostou et aI., 1990; Krantz, 1991). EPO and EPO receptor knockout
embryos have a detached epicardium, vascular abnormalities and a reduction in
proliferating myocytes and will die from cardiac dysfunction and anemia by E13.5 (Wu et
aI., 1999). EPO has been shown to be a trophic factor for cardiomyocyte proliferation
following its secretion from the epicardium (Stuckmann et aI., 2003). EPO could playa
role in regulating cell adhesion molecules since its phenotype is similar to both RXRa-/(Jenkins et aI., 2005) and N-cadherin-/- (Luo et aI., 2006) mice but this is currently
unknown. It has been noted previously that EPO levels are reduced in the RXRa-/mouse and that the EPO gene is a direct target of retinoid signaling (Makita et aI., 2005)
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suggesting a link between RXRu-/- phenotype and the EPO knockout phenotype. Early
fetal hypoxia can cause epicardial detachment and thinning of the ventricular
myocardium (Ream et aI., 2008). One hypoxia induced target gene is EPO (Ream et aI.,
2008) suggesting the importance of EPO signaling for epicardium attachment.
Epicardial-specific knockout of Alk5

(TGF~

type I receptor) resulted in embryos

with a detached epicardium, thinning of the ventricular myocardium, decreased
myocardial cell proliferation and decreased epicardial EMT (Sridurongrit et al., 2008).
These embryos also have a downregulation of N-cadherin and zona occludens 1 (Z01)
(Sridurongrit et aI., 2008). Z01 is known to interact with Connexin 43 (Cx43) in formation
of gap junctions (Gourdie et aI., 2006). Cx43 knockout mice have outflow tract defects,
coronary artery defects, epicardial bubbling similar to the RXRa-/- mouse and defects in
epicardial EMT (Rhee et al., 2009). Cx43 is known to be involved in the formation of gap
junctions between cells and is necessary for the electrical conduction system of the
heart. These studies point to the importance of proper epicardial cell signaling for
epicardium function because decreased gap junction formation and decreased growth
factor receptors can result in epicardial defects.
The RXRu-/- mouse is a model of aberrant epicardium formation. Phenotypically
this mouse displays a detachment of the epicardium from the myocardium, hypoplastic
ventricular myocardium and defects in septation and outflow tract (OFT) formation
(Jenkins et aI., 2005; Sucov et aI., 1994) (Figure 6). The RXRa-/- mouse will be
discussed further later in this chapter.

2S

Figure 6: Epicardial phenotype of the RXRa-/- mouse. The WT seen in whole mount (A)
and H&E section (C) shows normal architecture of the epicardium. The RXRa-/- heart
seen in whole mount (8) and H&E section (D) shows a bubbling of the epicardium
indicated by the arrowhead and arrow in D. The hypoplastic ventricular myocardium can
also be seen in the RXRu-/- heart section in D. (Taken from Jenkins et ai, 2005)
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E. Cell Adhesion
Cell-cell interactions are important to all development processes and formation
and maintenance of tissues and organs. In order for the epicardium to form and function
properly, appropriate cell-cell and cell-extracellular matrix adhesions need to be in place.
There are several types of cell-cell junctions that can be found in an organism including
tight junctions, gap junctions, desmosomes, hemidesmosomes, adherens junctions and
focal adhesions. Both adherens junctions and focal adhesion complexes serve to
connect the cell membrane to the actin cytoskeleton (Niessen, 2007; Wozniak et aI.,
2004). Desmosomes are found within epithelia and muscle and are capable of resisting
shear forces that can occur in these two tissues. The components of a desmosome will
connect the cell membrane with the cell cytoskeleton and one cell membrane to another
cell membrane to form a strong junction (Green and Simpson, 2007). Improper
functioning or formation of desmosomes has been implicated in skin blistering diseases
(Has and Bruckner-Tuderman, 2006). This would indicate that proper desmosome
function is necessary for adhesion since with loss of desmosomes function there is a
"bubble-like" detachment, similar to the epicardium in the RXRa-/- mouse. Cadherins
are a family of cell adhesion molecules that are found mainly in adherens junctions and
desmosomes (Elangbam et aI., 1997) and attach the cell to the actin cytoskeleton using
interactions with catenins (Wheelock and Johnson, 2003). Desmosomes in particular
contain two specialized cadherins that interact with intermediate filaments (Green and
Simpson, 2007). N-cadherin knockout mice have a detached epicardial phenotype (Luo
et aL, 2006), indicating the importance of cellular junctions in epicardial cell attachment
to the myocardium.
The focal adhesion complex is important for cell migration as well as transient
cell adhesion. Focal adhesions bind cells to the extracellular matrix or to other cells
through integrins. The focal adhesion complex consists of focal adhesion kinase (FAK),
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fibronectin (FN), VCAM-1, integrins, paxillin and various other ECM proteins (Wozniak et
aI., 2004) (Figure 7), FAK is a tyrosine kinase that will interact directly with integrins and
other proteins attracted to the focal adhesion such as paxillin (Wozniak et aI., 2004)
(Figure 7), Fibronectin will induce tyrosine phosphorylation of FAK following binding to
integrin heterodimers (llic et aI., 1995). Paxillin has been shown to be involved in
fibronectin-dependent cell migration, as was illustrated by the loss of cell migration on
fibronectin in paxillin null primary cell culture (Hagel et aI., 2002). There is decreased
tyrosine phosphorylation of FAK in paxillin null mice, which indicates a role for
fibronectin, FAK and paxillin in cell migration (Hagel et aI., 2002).
FN is an extracellular matrix glycoprotein that is expressed in the proepicardium,
epithelial basement membranes, connective tissues, vessel walls and muscles of the
mouse embryo and is involved in the focal adhesion complex through its binding to
integrins (Hynes, 1985; Kalman et aI., 1995; Peters and Hynes, 1996). FN contains a
specific RGD sequence that is recognized by the fibronectin-binding integrins to mediate
signaling and cell-matrix attachment (Hynes, 1992). FN-/- embryos die at gastrulation as
a result of defects in mesodermally-derived tissues (George et al. , 1993), Epicardium
formation in FN-/- cannot be studied because of the early embryonic death. Previously it
has been shown that FN is increased in the RXRa-/- heart and might playa role in
epicardium formation (Jenkins et aI., 2005).
Integrins are transmembrane receptors that aid in cell adhesion and attachment
of the cell to the extracellular matrix and to neighboring cells (Hynes, 1992). Integrins
are composed of a and

~

subunits which can form 24 different integrin heterodimers

(Hynes, 2002). The integrin heterodimers

a5~1, a8~1

and

aV~1

will bind to FN at the

RGD (arginine-glycine-aspartate) sequence within the FN protein (Hynes, 2002). The
heterodimer a4~ 1 will also bind FN although it primarily binds VCAM-1, which will also
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Figure 7: Signaling pathways downstream of VCAM-1 or FN binding to integrin a4~1.
This diagram illustrates the major signaling pathways that occur downstream of integrin
a4~1 binding to VCAM-1 or fibronectin. VCAM-1 binding is shown in the diagram but
integrins can also bind to fibronectin and initiate signaling.
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bind FN (Kwee et aI., 1995) (Figure 7). Other integrin heterodimers bind different
extracellular matrix molecules including laminins that do not possess RGD sequences
(Hynes, 2002). After binding their particular ligand, integrins will activate signaling
processes such as proliferation, cell motility, cell survival, cytoskeletal organization and
transcriptional control (Hynes, 2002). Integrins are referred to as "outside-in"
transducers, receiving signals from extracellular components and then sending signals
within the cell (Hynes, 2002).
Integrin a4 and as are expressed in the proepicardium and epicardium of the
mouse (Pinco et aI., 2001). Integrin a5 knockout mice have defects in the posterior
trunk, have malformed yolk sac blood vessels and display defects in embryonic blood
vessels, but exhibit no heart defects (Yang et aI., 1993). Integrin a4 knockout mice have
no epicardium resulting in coronary artery and myocardial defects (Yang et aI., 1995)
(Figure 3). Integrin a4 has been shown previously to be required in EPDCs to initiate
FN-mediated migration (Sengbusch et aI., 2002). Inhibiting integrin a4 by using
adenovirus expressing antisense integrin a4 in chick epicardial cells resulted in
stimulation of EMT, increased migration and invasion of EPDCs into the underlying
myocardium and inability to become smooth muscle cells in the coronary vasculature
(Dettman et aI., 2003). While it is known that integrin a4 is involved in epicardium
formation, its role in maintenance of epicardium attachment and epicardium function is
not entirely known. The RXRa-/- mouse has a defect in epicardial EMT (Ruiz-Lozano
and Kubalak, unpublished) hence disrupting cell adhesion could have an adverse affect
on EMT.
VCAM-1 is a transmembrane protein that was originally identified for its
involvement in adhesion of leukocytes expressing integrin a4 during the inflammatory
response (Elangbam et aI., 1997). The primary function of VCAM-1 is to mediate
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intercellular adhesion with the integrin

a4~ 1

heterodimer. VCAM-1 is expressed in a

number of cell types including vascular endothelial and smooth muscle cells, bone
marrow cells, and myocardial cells (Rosen et aI., 1992; Sheppard et aI., 1994),
Expression in the heart can be found in the myocardium especially in the interventricular
septum and outflow tract myocardium (Kwee et aI., 1995), The VCAM-1 binding partner
integrin 0.4 is expressed in the epicardium and also in the endocardial cushions (Kwee et
aI., 1995), The VCAM-1 knockout is embryonic lethal as a result of either loss of
extraembryonic circulation or heart defects including a failure to form the epicardium
(Kwee et aI., 1995). One study showed that VCAM-1 expression will increase in cultured
cardiomyocytes and NIH3T3 cells in response to an epicardial-derived factor (serum-free
conditioned media from cultured epicardial cells) (Kang and Sucov, 2005). In this same
study, VCAM-1 m RNA levels were reported to be reduced in the E 11 ,5 RXRa-/- heart
(Kang and Sucov, 2005) (Figure 13). However, a complete developmental profile of
VCAM-1 in the mouse was not done. VCAM-1 is necessary for epicardium formation
with loss of VCAM-1 resulting in failure to form an epicardium (Kwee et aI., 1995),
however, the role of VCAM1 in events following epicardium formation is unknown. In
this study VCAM-1 was examined through analysis of its expression in the RXRa-/mouse model of aberrant epicardium formation.

F. Retinoid signaling during heart development
Retinoic acid signaling is important for a wide variety of events during veterbrate
embryonic development including cell proliferation, apoptosis, cell differentiation and
tissue homeostasis (Mark et at., 2006). VAD in vertebrates results in defects such as
malformations of the eye, heart, respiratory system and urogenital system (Mark et a!.,
2006; Wilson and Warkany, 1949). Retinoic acid isoforms (all-trans retinoic acid and 9-
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cis retinoic acid) are derivatives of vitamin A. Retinoids are ligands for the retinoid
receptors, which when activated will translocate into the nucleus, dimerize and either
activate or inhibit transcription. There are two types of retinoid receptors: retinoic acid
receptors (RARs) and RXRs, with an u, ~ and y subtype of each (Chambon, 1996).
RARs will bind all-trans (at-RA) and 9-cis retinoic acid (9-cisRA) while RXRs will bind
only 9-cisRA for activation (Chambon, 1996; Mark et aI., 2006) (Figure 8). Hetero- or
homodimers of retinoid receptors will control transcription of RA-target genes by binding
to retinoic acid response elements (RAREs) on DNA (Chambon, 1996) (Figure 8). Once
9-cisRA or at-RA binds to the RAR/RXR heterodimer or receptor homodimer, the
complex will bind to the DNA and up- or downregutate transcription (Chambon, 1996;
Mark et aI., 2006) (Figure 8). RARs and RXRs can also dimerize with thyroid hormone
receptors, vitamin D3 receptors (Mark et aI., 2006), farnesoid X receptor, peroxisome
proliferator-activated receptors (PPARs) and liver X receptor (Desvergne, 2007) to
initiate transcription.
Vitamin A is converted to retinol in the body and is then further metabolized to
retinal and finally to at-RA and 9-cis-RA. RALDH2 is a retinoic acid-synthesizing
enzyme responsible for the conversion of retinal to at-RA (Duester, 2000) (Figure 8). In
chick and mouse, RALDH2 is expressed in the proepicardium and continues to be
expressed in the proepicardial buds and epicardium suggesting a role for RALDH2 in
epicardium development (Hoover et aI., 2008a; Moss et aI., 1998; Niederreither et aI.,
1997; Xavier-Neto et aI., 2000) (Figure 9). In the chick model, epicardially-derived cells
that express RALDH2 are contained within the subepicardial space and then invade the
ventricular myocardium (Perez-Pomares et aI., 2002). As these cells differentiate into
smooth muscle and endothelial cells, RALDH2 is downregulated (Perez-Pomares et aI.,
2002). RALDH2 knockout mice have heart defects that include decreased
cardiomyocyte proliferation and ventricular trabeculation suggesting a role for epicardial
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Figure 8: Retinoid signaling and cardiovascular phenotypes resulting from knockout of
pathway components. RAR, retinoic acid receptor; RXR, retinoid X receptor; RBP,
retinol binding protein; RoDH, retinol dehydrogenase; CRBP, cellular retinol binding
protein; RARE, retinoic acid responsive element; 9-cisRA, 9-cis retinoic acid; atRA, alltrans retinoic acid; RALDH, retinaldehyde dehydrogenase; CYP1 81, cytochrome P450
181; CYP26, cytochrome P450 26; CRASP, cellular retinoic acid binding protein
(Adapted from Hoover et ai, 2008)
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Figure 9: Immunohistochemical (IHC) analysis of RALDH2 expression in the mouse
heart from E9.5-E11.S. RALDH2 expression is detected in the PE at E9.S (8 and C), in
the remaining PE, PE buds and newly formed epicardium at E1 0.5 (E and F) and in the
epicardium and body wall at E11.S (H and I).
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RALDH2 since these processes require a functional epicardium (Niederreither et aI.,
2001). RXRa has been shown to have a similar expression pattern to RALDH2 in avian
embryos, with expression being seen in the epicardium, some subepicardial
mesenchymal cells and EPDCs (Guadix et aI., 2006). The similar expression patterns of
RXRa and RALDH2 indicate that retinoid signaling is highly important in epicardium
development and function.
Cardiac defects have been reported to be associated with several com ponents of
the retinoid pathway including RALDH2 and VAD models (mentioned above) (Figure 8).
Cytochrome P450 26 (Cyp26) is responsible for converting at-RA to inactive metabolites
(Figure 8). Loss of Cyp26 leads to defects in cardiac looping (Sakai et aI., 2001).
STRA6 is a cell surface receptor that is specific for retinol binding protein (RBP) that
delivers retinol into the cell (Figure 8). Autosomal recessive mutations of STRA6 have
been reported in the human population and are associated with a condition known as
Matthew-Wood syndrome (Pasutto et aI., 2007). The heart defects associated with this
syndrome include Tetrology of Fallot, aortic arch defects, septal defects and persistent
ductus arteriosus (Pasutto et al., 2007). Defects associated with Cyp26 and STRA6
further indicate the importance of proper retinoid signaling with heart development.
Targeted deletions of several of the RARs and RXRs exist (Kastner et aI., 1997;
Lee et aI., 1997; Luo et aI., 1996; Mendelsohn et aI., 1994); however, knockout of RXRa
is the only single RA receptor knockout that results in cardiac malformations (Sucov et
al. , 1994). Combination RA receptor knockouts have a phenotype that resembles VAD
(Mark et aI., 2006). The RXRa-/- mouse has a thin myocardium, improper septation of
the outflow tract, hypoplastic endocardial cushions, delay in epicardium formation and
detached epicardium (Jenkins et aI., 2005; Kubalak et aI., 2002; Sucov et aI., 1994).
Using a floxed RXRa mouse line, RXRa has been conditionally knocked out in the
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different cell lineages in the heart including the ventricular myocardium [using MLC2Vcre (Chen et aI., 1998)], neural crest cells [using Pax3-cre (Ruiz-Lozano and Chien,
2003) and Wnt-1-cre (Merki et aI., 2005)] and endocardial cells [using Tie2-cre (Merki et
al.,2005)]. Epicardial-specific RXRa knockout (using GATA-5-cre) is the only region of
the heart where specific removal of RXRa produced a cardiac phenotype that resembled
the systemic RXRa-/- illustrating the importance of retinoic acid signaling within the
epicardium (Mark et aI., 1999; Merki et aI., 2005). These mice have defects in the
coronary arteries (abnormal branching), thinning of the myocardium, detachment of the
epicardium and thinning of the subepicardium (Merki et aI., 2005). There is also
downregulation of

~-catenin

(Merki et aI., 2005), which is known to be involved in cell

adhesion through interactions with N-cadherin.
Secretion of retinoic acid and EPO from the epicardium appears to be required
for cardiomyocyte proliferation (Stuckmann et aI., 2003). In response to retinoic acid
and requiring a functional RXRu, the fetal epicardium will secrete trophic factors, such
as fibroblast growth factor 2 (FGF2), that help promote ventricular chamber
morphogenesis (Chen et aI., 2002; Smith and Bader, 2007) by activating the P13K1Akt
and Erk pathways to promote cell proliferation (Kang and Sucov, 2005). At this time it is
not entirely known if proper epicardial cell adhesion is necessary for signaling to the
myocardium but it is likely. The RXRa-/- mouse also has a loss of mitogenic signals
from the epicardium as well as a reduction in the proliferative rate of ventricular
cardiomyocytes (Kang and Sucov, 2005). The expression of VCAM-1 was reduced in
the E11.5 RXRa-/- (Kang and Sucov, 2005), suggesting that this extracellular matrix
molecule is likely regulated by retinoic acid receptor.
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G. Transforming Growth
TGF~2

Factor-~

signaling

is found in the proepicardium, epicardium and ventricular myocardium

during heart development (Molin et aI., 2003) (Figure 10) and, importantly, is elevated in
the RXRa-/- mouse (Kubalak et aI., 2002).

TGF~2

is a member of the

TGF~

superfamily

of signaling proteins (Derynck and Feng, 1997) and has been shown to playa role in
cardiovascular development (Harvey, 1999). Other members of this signaling family
include

TGF~1, TGF~3,

Derynck, 2005).

TGF~1

bone morphogenetic proteins (BMPs) and activins (Feng and
is expressed in the vascular endothelium and endocardium,

particularly in the endocardium overlying the atrioventricular region and ventricular
trabeculae (Molin et aI., 2003) (Figure 10). TGFB2 (Figure 10) and TGFB3 are
expressed in the epicardium, endocardial cushions and fibrous structures of the heart
(Molin et aI., 2003) indicating that these signaling molecules are especially relevant to
epicardium formation and function.
TGF~2

is secreted as a latent protein (as are

TGF~1

and TGFB3), which is then

proteolytically cleaved and activated (Derynck and Feng, 1997). TGFB2 binds to the
TGFB type II receptor, inducing heterodimerization with the type I receptor (Derynck and
Feng, 1997) (Figure 11). The type II receptor phosphorylates the type I receptor through
intrinsic serine/threonine kinase activity (Derynck and Feng, 1997). The type I receptor
then phosphorylates the receptor-activated Smads (R-Smads) Smad2 and Smad3
(Derynck and Feng, 1997) (Figure 11). Once a R-Smad is activated by phosphorylation,
it dimerizes with the co-Smad, Smad4, translocates into the nucleus and binds to DNA to
regulate gene transcription (Figure 11). The R-Smad/Smad4 complex, once inside the
nucleus, activates transcription by assembling with a nucleoprotein complex at Smad
consensus DNA-binding sites (Feng and Derynck, 2005) (Figure 11). This nucleoprotein
complex includes Smad-binding elements on the DNA, DNA-binding transcription factors
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Figure 10: TGF~ mRNA expression in the mouse heart at E9.S. TGF~1 transcripts (B, E
and H) are detected in the endocardium, dorsal mesocardium (arrow in B) and dorsal
aorta. TGF~1 mRNA was not detected in the myocardium or PE (B). TGF~2 mRNA (C,
F and I) is expressed in the myocardium, endocardium, PE (arrowhead in C) and newly
formed epicardial cells (arrow in C). (Taken from Molin et aI., 2003)
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and transcriptional coactivators (Feng and Derynck, 2005). In order to stop signaling
through Smads, the inhibitory Smad, Smad7, is induced by Smad3 and serves as a
negative regulator (Feng and Derynck, 2005). The inhibitory Smad7 competes with the
receptor-activated Smads for receptor interaction (Moustakas et aI., 2001).
Knockout of TGF~2 results in cardiovascular defects including ventricular and
outflow tract septal defects, hypoplastic ascending aorta, dual outlet right ventricle and
dual inlet left ventricle (Sanford et aI., 1997), but no reported epicardial defects. The
mutant mice die perinatally due to respiratory distress possibly as a result of
cardiovascular dysfunction (Sanford et aI., 1997).

TGF~2

is the only

TGF~

isoform that

is expressed in the proepicardium (Molin et aI., 2003) (Figure 10) suggesting it may be
important for development of the epicardium. TGF~2 is also localized to the developing
outflow tract and cardiomyocytes (Molin et aI., 2003) (Figure 10) and is known to be an
activator of EMT and possible regulator of apoptosis in endocardial cushions
(Camenisch et aI., 2002; Kubalak et aI., 2002). At this time, no epicardial defects have
been reported or observed by in

TGF~2-/-

mice. Interestingly, the RXRu-/- mouse heart

has elevated TGF~2 expression during midgestation (Kubalak et aI., 2002) (Figure 12)
and potentially during early heart development (Jenkins and Kubalak, unpublished data).
We hypothesize that increased

TGF~2

plays a role in the abnormal epicardium formation

seen in the RXRu-/- mouse, indicating the need to explore the

TGF~2

signaling pathway

further in epicardium attachment and proper epicardium function

H. The retinoid X receptor knockout (RXRa-I-) mouse
The RXRu-/- mouse is the only single retinoid receptor knockout to result in
congenital heart disease. The RXRu-/- mouse has a thin myocardium, improper
septation of the OFT and hypoplastic endocardial cushions and is embryonic lethal

46

between E13.5 and E15.5 (Gruber et aI., 1996; Sucov et aI., 1994). RXRu-/- mice also
have an increase in apoptosis in the outflow tract and elevated

TGF~2

at midgestation

(Kubalak et aI., 2002) (Figure 12). In addition to its cardiac defects, the RXRu-/- mouse

..

also has decreased liver mass as well as edema and ocular defects (Kastner et aI.,
1994; Sucov et aI., 1994).
The RXRa-/- mouse has, among other cardiac defects, a defect in epicardium
development (Jenkins et aI., 2005) (Figure 6). Epicardium formation in the mutant is
delayed and, once the epicardium forms, is detached from the myocardium (Jenkins et
aI., 2005). There are several areas of bare myocardium in the RXRu-/- heart up until
E11.5 when the wild type mouse epicardium is fully formed (Jenkins et aI., 2005). By
E12.5, the RXRa-/- mouse has epicardium fully covering the heart, however, it is
detached from the myocardium (Jenkins et aI., 2005) (Figure 6). A decrease in VCAM-1
mRNA in the E11.5 RXRu-/- heart was also reported (Kang and Sucov, 2005) (Figure
13), indicating VCAM-1 may be important in the RXRa-/- mouse phenotype since it has
previously been shown to be involved in epicardium formation (Kwee et aI., 1995).
However, the study by Kang and Sucov did not do a complete developmental profile of
VCAM-1 in the developing heart. This detachment from the underlying myocardium may
be due to an increase in subepicardial extracellular matrix production or a defect in
epicardium/myocardium attachment. In this study, epicardial cell attachment will be
further studied by analyzing adhesion proteins in the RXRu-/- mouse.
The phenotype of the RXRu-/- mouse heart may largely be due to improper
development and functioning of the epicardium since loss of EPDCs or fewer EPDCs
can lead to many of the defects seen in the RXRu-/- heart such as thinning of the
myocardium. In previously published reports, the RXRa-/- mouse was shown to have
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Figure 12: Elevated TGF~2 protein and mRNA in the heart of the RXRu-/- mouse.
mRNA levels are elevated in the heart but not TGF~1 in the RXRu-/- shown by
RNase protection (A). Immunohistochemical analysis of E13.5 (8) and E12.5 (C) WT
and RXRu-/- heart shows that TGF~2 levels are elevated in the RXRu-/- mouse.
(adapted from Kubalak et ai, 2002)
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Figure 13: Real time PCR analysis of VCAM-1 mRNA in the heart of the RXRa.-/- mouse
at E11.S. Real time quantitative PCR shows a decreased level of VCAM-1 in the
RXRa.-/- mouse heart at E11.S. (Adapted from Kang and Sucov, 2005)
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increased TGF~2 in the heart during midgestation (Kubalak et aI., 2002) (Figure 12).
Previous studies suggest that TGF~2 is increased in the proepicardium using RNase
protection analysis of proepicardium of wr versus RXRu-/- (Jenkins and Kubalak,
unpublished). The increased

TGF~2

could be regulating proteins that are altered in the

RXRu-/- mouse such as VCAM-1. RXRu-/- mice also have a reduction in GSK3~
phosphorylation (downstream of P13K1Akt pathway) and p90rsk (downstream of Erk)
phosphorylation (Kang and Sucov, 2005). Both of these pathways are known to be
involved in cardiomyocyte proliferation, indicating that retinoid signaling is important for
cardiomyocyte proliferation. One study showed that the RXRu-/- mouse has reduced
expression of NADH-ubiquinone oxidoreductase (mitochondrial complex I), reduction in
ATP content in ventricular tissue and misexpression of several genes involved in the
electron transport chain (Ruiz-Lozano et aI., 1998). The authors indicated that the
hearts of RXRu-/- mice are energy deprived, which could contribute to embryonic
lethality from impaired heart function.
Previous studies have also shown that the levels of the extracellular matrix
molecule fibronectin is increased in the proepicardium, epicardium and body wall of the
RXRu-/- mouse heart and thus, may playa role in the abnormal development of the
mutant heart (Jenkins et aI., 2005). Levels of fibronectin protein within RXRu-/- PE
explants also appears to be elevated and disorganized in comparison to the fibronectin
network in the wild type PE explants (Jenkins et aI., 2005), which could disrupt binding
with integrins. In PE explants from the RXRu-/- mouse, migration of PE-derived cells is
reduced compared to wild type, which may explain the delay in epicardium formation.
There is also an increase in apoptosis within the PE of the RXRu-/- mouse (Jenkins et
aI., 2005), which may also contribute to the delay in epicardium formation because fewer
PE cells would be available to migrate to the heart.
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Knockout of RXRa specifically in the epicardium results in thinning of the
myocardial wall as well as defects in coronary arteriogenesis (Merki et aI., 2005). The
epicardial-specific RXRa knockout demonstrated that the epicardium is the only cell
lineage of the heart where RXRa can be specifically knocked out and produce a
phenotype illustrating the importance of retinoic acid signaling within the epicardium
(Mark et aI., 1999; Merki et aI., 2005). These mice have defects in the coronary arteries
(abnormal branching), thinning of the myocardium, detachment of the epicardium and
thinning of the subepicardium (Merki et aI., 2005). The coronary artery defect was not
reported in the original paper describing the systemic RXRa-/- mouse (Sucov et aI.,
1994). In the epicardial-specific RXRa-/- mouse there is a down-regulation of FGF2,

~

catenin and Wnt9b, all of which are known to be important in epicardial EMT and
vasculogenesis (Merki et aI., 2005). Re-expression of RXRa specifically in the
myocardium for RXRa-/- hearts is unable to rescue the thin myocardium phenotype
suggesting that the thinning of the myocardium is not due to loss of RXRa-/- in the
myocytes (Subbarayan et aI., 2000).
The cell adhesion molecule VCAM-1 has previously been shown to be required
for epicardium formation (Kwee et aI., 1995). VCAM-1 was altered in the RXRa-/mouse heart with a decrease seen at E11.5 compared to the WT (Kang and Sucov,
2005). Based on its known role in epicardium formation through adhesion of the
epicardium to the myocardium (Kwee et aI., 1995) and in inhibiting epicardial EMT
(Dokic and Dettman, 2006), it is thought that VCAM-1 could have a role in epicardium
adhesion and epicardial EMT in the RXRa-/- mouse. This current study aims to analyze
VCAM-1 in the RXRa-/- model of aberrant epicardium formation during E9.5-E13.5 and
determine if the retinoid and/or TGF~2 signaling pathway is responsible for its regulation.
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The overall hypothesis to be tested in this dissertation is that proper expression
of VCAM-1 is essential for normal cardiac morphogenesis and is regulated by TGF~2
and/or retinoid signaling during formation of the epicardium. To address this hypothesis
there are two specific aims:

Aim 1: To determine the expression pattern and levels of VCAM-1 in E9.5-E13.5

RXRu-/- versus wild type (WT) hearts.

Aim 2: To determine how TGF~2 and/or retinoid signaling regulate VCAM-1 expression
during heart and epicardium development
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Chapter 2: Materials and Methods

Transgenic Mice and Embryos

RXRu+/- breeders were maintained as previously described on a C57BL6
background (Sucov et aI., 1994). RXRu+/- mice were crossed to yield WT and RXRu-/embryos to use for some experiments (immunohistochemistry, western blot, real time
PCR and epicardial explants). WT mice were crossed to yield WT embryos to use for
epicardial explants and whole embryo culture (WEC). Timed pregnant females were
sacrificed using isofluorane followed by cervical dislocation on the appropriate
embryonic day for experimentation. Embryos were staged using the day of plug as
embryonic day (E) 0.5. Embryos were removed from the uterus and yolk sac then
dissected according to each experiment.

Immunohistochemistry

Whole embryos (E9.0-E12.5) from RXRu+/- matings were bisected and fixed in
2% paraformaldehyde for 1 hour at room temperature (RT). A portion of the tail of each
embryo was removed for genotyping. Wild type and mutant littermates were dehydrated
through graded ethanols and embedded in paraffin for sectioning. The paraffin
embedded tissues were sectioned at 5!lm and mounted onto slides (Fisher Superfrost
plus). A guide series of each embryo (every ninth section) was made and hemotoxylin
and eosin stained to use as a reference. Slides were deparaffinized in xylenes,
rehydrated in graded ethanols and washed in 1x phosphate buffered saline (PBS).
Slides were blocked in a blocking solution with 1% bovine serum albumin (BSA), 0.01 %
Tween 20 in 1x PBS for 1 hour. Sections were incubated in primary antibody diluted in
blocking solution overnight at 4

cc.

The primary antibodies used were rabbit anti-VCAM-
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1 H276 (Santa Cruz Biotechnologies), rabbit anti-integrin a4 (Abcam 65984) and rabbit
anti-N-cadherin (Abcam 12221). The following day, sections were washed with 1x PBS,
incubated in anti-rabbit secondary antibody conjugated to Alexa-488 or Alexa-594 from
Molecular Probes diluted in blocking solution, for 2 hours and washed in 1x PBS.
Following PBS wash, sections were nuclear stained using ToPr03 nuclear stain
(Invitrogen Molecular Probes) for 10 minutes then washed. Slides were coverslipped
using OABCO in PBS and a glass coverslip, sealed with nail polish (Fisher) for
microscopic analysis. The fluorescently stained tissue sections were viewed on a Leica

rcs SP2 AOBS confocal microscope.

To compare

wr and RXRa-I-,

constant gain and

laser settings were used throughout the analysis.

Western Blottingllmmunoblotting

Samples of whole heart were taken from wild type and mutant embryos. The
genotypes of the embryos were determined by PCR following dissection as described
above. Protein was extracted from single hearts in 20l-l1 RIPA (20 mM Tris pH 7.5, 100
mM NaCI, 0.5% NP-40, 0.5 mM EOTA, 0.5 mM PMSF) buffer containing protease
inhibitors (Complete mini, Roche) and sonicated until the tissue was disintegrated.
Protein samples were centrifuged at maximum speed for 10 minutes at 4°C to pellet any
cell debris. The supernatant was removed and 6x loading buffer (200 mM Tris-HCI pH
6.8, 50% glycerol, 8% SOS, 400 mM OTT, 0.4% Bromophenol blue) was added to each
sample to a final concentration of 1x. Samples were heated at 95°C for 5 minutes and
then loaded onto a 10% Tris-HCI gel along with Precision Plus Kaleidoscope Standard
molecular weight marker (Biorad). The gel was run for 45 minutes at 60 volts (V) then
for an additional 2-3 hours at 130V. Following electrophoretic separation, the gel was
equilibrated in transfer buffer for 20 minutes. PVOF (GE water and processing
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technology) membrane was cut to the appropriate dimension (8.5cm x 5.5cm), activated
in methanol for 1 minute, washed in water for 10 minutes then equilibrated in transfer
buffer for 10 minutes. Blot paper (BioRad) was cut to appropriate dimensions (gcm x
6cm) and equilibrated with transfer buffer. A Transblot semi-dry transfer cell (BioRad)
was used to transfer the proteins from the gel to the PVDF membrane. Protein transfer
was done at 20V for 30 minutes. Once proteins were transferred, the blot was rinsed in
1XTBST (Tris-buffered saline containing 0.01%) Tween20). After washing, the blot was
blocked in 5x blocking buffer (TBST with 5% dry milk) for 1 hour. Primary antibody
(rabbit anti-VCAM-1 H276) was diluted to 1:500 in 1x blocking buffer and incubated with
the blot overnight at 4°C. The following day, the blot was washed for 1 hour with TBST,
incubated in horseradish peroxidase (HRP) conjugated anti-rabbit secondary antibody
diluted 1: 10,000 in 1x blocking buffer, then washed with TBST for 1 hour. The blot was
incubated with West Femto (Pierce) solution per the manufacturer's recommended time
and developed using autoradiography film (Hyperfilm, Amersham). Blots were stripped
for probing with different antibodies using ReBlot mild solution (Millipore) as per
manufacturer's recommendations. Blots were scanned for quantification of protein
levels using Image J (NIH) for densitometry and normalized to

~-tubulin.

Real time PCR (RT -PCR)
Intron-spanning primers were designed for each mRNA of interest and checked
for specificity to the gene of choice by using BLAST on the NCBI website
(http://www.ncbi.nlm.nih.gov.ezproxy.musc.edu/BLAST/). The intron-exon boundaries of
each gene were mapped and primer sets designed to span an intron in order to verify
that we were amplifying cDNA and not genomiC DNA in the PCR.
Sequences of the primers were:
Integrin a4 F: 5' CCCACAGGCCTTTATTTCAT
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Integrin a4 R: 5' CTATCCTTGAGAGGCGATCC
VCAM-1 F:

5' CACTCTTACCTGTGCGCTGT

VCAM-1 R:

5' CTCCAGATGGTCAAAGGGAT

GAPDH F:

5' AACTTTGGCATTGTGGAAGGGCTC

GAPDH R:

5' TGGAAGAGTGGGAGTTGCTGTTGA

N-cadherin F: 5' ATGCCCAAGACAAAGAAACC
N-cadherin R: 5' CTGTGCTTGGCAAGTTGTCT
TGF~2

F:

5' GCTTTGGATGCTGCCTACTGCTT

TGF~2

R:

5' TGTACAGGCTGAGGACTTTGGTGT

RNA was isolated from whole hearts of RXRa-/- and wild type mice using RNA
Stat60 (Tel-Test, Inc) per manufacturer's recommendations. The amount of RNA was
quantified by UV absorbance at 260nm. Complementary DNA (cDNA) was made from 1
Ilg RNA samples using M-MLV reverse transcriptase (Promega) and Oligo dT (Gibco).
Real time reverse transcriptase (RT) PCR was performed using SYBR green (BioRad)
per manufacturer's protocol using the BioRad iCycler. All reactions were performed in
triplicate. Relative mRNA levels in each sample were determined based on differences
between the cycle thresholds (Ct) for each amplicon. The delta Ct was determined by
subtracting the Ct value of the GAPDH from the Ct value of the gene of interest. The
fold change between WT and RXRa-/-was determined using the delta delta Ct method
(Schefe et aI., 2006).

Transmission Electron microscopy (TEM)
Embryos fixed in 2%) glutaraldehyde were sent to the Instrumentation Resource
Facility at the University of South Carolina School of Medicine in Columbia, SC where
Dr. Robert Price's lab performed the TEM analysis. Images were analyzed in
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collaboration with Dr. Price to look for differences in cellular junctional complexes
between the epicardium and myocardium of the E1 0.5

wr and RXRa-I-.

In silico promoter analysis
The VCAM-1 promoter sequence was obtained from the NCBI database
(Accession number: U42327) and analyzed using the Transcription Element Search
System (TESS) program (http://www.cbil.upenn.edu/cgi-bin/tess/tess). Smad binding
elements and retinoid binding sites were also searched for manually within the promoter
to ensure that al possible sites were identified.

Rat epicardial (REC) cells
Rat epicardial (REC) cells were obtained from Dr Robert Gourdie at the Medical
University of South Carolina in Charleston, SC and were maintained as described (Wada
et aI., 2003). The cells were grown in media consisting of Dulbecco's Modified Eagle
Medium (DMEM 4.5 gIL, Gibco) supplemented with 10% fetal bovine serum (Gibco),
penicillin-streptomycin and L-glutamine at 37°C and 5% C02. Cells were passaged
using 0.05% trypsin EDTA (Gibco) at 37°C and then plated according to the specific
experimental protocol being used. REC cells were used for chromatin
immunoprecipitation and VCAM-1-luciferase analysis.

Chromatin immunoprecipitation (ChiP)
REC cells (100,000 cells) were seeded onto 35 mm dishes and grown until 90%
confluent. Each dish of cells was fixed with 37% formaldehyde to covalently crosslink
proteins to the DNA. ChiP was performed using the EZ ChiP kit from Millipore per the
manufacturer's instructions. Briefly, chromatin was harvested from the cells by adding of
SDS lysis buffer (Millipore), scraping cells into an eppendorf tube and pelleting the cells.
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DNA was sheared by sonication 4-5 times in a water bath sonicator containing ice until
DNA was sheared to fragments of 200-1000 basepairs (approximately 5 minutes). DNA
was analyzed on an agarose gel to assure the proper shearing of the DNA. Sheared
DNA was diluted in Dilution Buffer (Millipore) to a 1:10 DNA:buffer ratio.
Protein G Agarose (Millipore) was added to the diluted sheared DNA and
incubated for 1 hour at 4°C to remove proteins and DNA that may bind non-specifically
to the Protein G agarose later in the procedure. Samples were centrifuged at low speed
(1000g) and the pellet was discarded. Ten III of each supernatant was saved to use as
the "input" sample. One milligram of the immunoprecipitating antibody was added to
each sample and incubated overnight at 4°C with rotation. Immunoprecipitating
antibodies used were anti-RNA polymerase (positive control-Millipore), RXRa (0-20,
Santa Cruz) and Smad4 (Santa Cruz). The negative control had normal mouse IgG
added instead of an antibody.
Protein G agarose was then added to each sample and incubated for 1 hour.
Samples were centrifuged at low speed and supernatant removed and discarded. The
agarose beads were first washed in low salt (Millipore) then high salt (Millipore) then LiCI
buffers (Millipore) followed by TE buffer. Samples were eluted in elution buffer
(Millipore) and crosslinked proteins were separated with 5M NaCI.

Samples were

incubated with RNase A, 0.5M EDTA, 1M Tris-HCI and Proteinase K and then purified
using the DNA purification system in the EZ ChiP kit (Millipore). DNA that was
crosslinked to RXRa or Smad4 will coprecipitate with the chromatin complex and can
then be analyzed using PCR.
A PCR reaction using primers to the VCAM-1 promoter or the GAPDH promoter
(as a positive control) was performed to determine if portions of the VCAM-1 promoter
DNA were bound by RXRa or Smad4. The PCR reaction consisted of a 95°C
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denaturation cycle for 5 minutes followed by 30 cycles of denaturation at 95°C for 1
minute, annealing at 60°C for 1 minute and extension at 72°C for 1 minute. A final
extension at 72°C was done for 10 minutes. PCR samples were run on a 2.5% agarose
gel containing ethidium bromide. DNA bands were visualized using a gel imager.
ChiP primers were as follows (Figure 14, highlighted in red):
VCAM-1 ChiP F:

TCCTGTCATCCAGCAATGGGTCAA

VCAM-1 ChiP R:

AACTGCCAACAGTGTGTGTGTGTG

GAPDH ChiP F:

CTGAGCAGACCGGTGTCACATC

GAPDH ChiP R:

GAGGACTTTGGGAACGACTGAG

TGF~2

and 9-cisRA treatments
Lyophilized

TGF~2

(R&D Systems) was reconstituted in diluent (4 mM HCI in

0.1 % BSA) at a 1Ong/~I concentration. Lyophilized 9-cisRA (MP Biomedicals) was
reconstituted in DMSO at a concentration of 100 mM. Most treatments were done in
serum-free DMEM to eliminate the variability from growth factors contained within
serum. The appropriate amount of TGFf32 and/or 9-cisRA was added to serum-free
DMEM depending on experiment (concentrations used are listed with each experiment)
and then added to cells in culture. In the case of whole embryo culture and luciferase
assays, the appropriate amount of TGF~2 and/or 9-cisRA was added directly to the
culture medium. Concentrations used of each varied depending on the experiment.
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Figure 14: Regulatory elements contained within the mouse VCAM-1 promoter region.
5' portion of the sequence of the mouse VCAM-1 promoter (accession number: U42327)
with putative and defined regulatory sites highlighted. Smad-binding elements are
highlighted in yellow. Retinoid elements are highlighted in blue. The TATA box is in
purple upstream of the start site indicated by the black arrow. E box sequences are
highlighted in green. ChiP primers used are highlighted in red.
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-1894 gatctacata gccacggaga gttctttagc tatatgttag agtagtggtt cttaaacgag gaaggatttg accttgtgga atccaccaaa tagttttttt
- 1794 tttcacttcc tctgttgtat gtactattct cctttcctga taggaattat ttctccactc acttgggtga gaactgatac caaataagat ga gtctgcat

SBE

-1694 gatccaagta gttatttatt tttaagtgtc aaagac atgg attaacattt tcttacatgc ctttgatcta tggagaaggt gagaatcagt agggggtag1..

SBE

SBE

-1594 ct atactctc cttttatgac atgacattgt tgaggtcctc tagatgacat ggcagctaat gtcatcgatc cctggatatg tcgtcatagc cctaaaatat
-1494 atccctcaac ttccctttta tacttgcctc tcagtgggag ccacatgtat tctcaagagg gaattcagaa gtct ctcctg ccaggttgga gcagttggcg

SBE

-1394 actgtggg Lc \;cactgatag cctttgtcca atgacatgat actgttaatt ttacatgtgc ccagatgtct. gggaactata cctttcttgt ggaattattt

SBE

-1294 ttttctc

SSE
gcactt atgaactaca ttcagtattt tgaacgtttc tcttctagat tttaaacatc tagaagatgc tgcaggtttt atagtcgtta

E Box

- 1194 tatataaaac cattatatat atatatatat atatatatat atatatatat atatatatat atggaataga aacaactatg aataagaact agtcctggcc
- 1094 atgcagggaa ctgataatgc catgtgggag gtaaacccac atgtgtataa tacaaggaag tggctattcc ggtttctttc tgatgggcaa gcattttgca
-994 aggacatggg ctatgcatgt gta agac cta cagaggcatt ta ,gacactt aattgagtc t ttcaaaaagt catttcactg ggagtagaaa ataataataa

SSE

SSE

SSE

-894 aaaaatggtt gtcaattcat ctcctaaagc taatctgttt acatattcaa ttggacttgt ggctaaataa tgcagccaaa gaaatccacc acaaaaattt
-794 agcagac aga tcccattttt tagcgttcaa gtct.gcaaaa gac

SSE

SSE

cctgt catccagcaa tgggtca ag ggctggggca ttgtcaaaca aaagaaaaga

retinoi

SSE

retinoid

-694 taattccctt cattctgcat caacgtcctt tcatttacta cttcagaaag ttatttcagg gaggtttttt ttttgtcaaa aattcactta tgaataaaag
-594 agtataaaaa taagaactac tgactcacat tctaaaagag tgactcatga taatgSlgtca ataaaaacaa ataaaggata ttttcctttt tttgttgaaa

retinoid
-494 gagaacaatt tttatttttt aaattgcaaa tgcatttctt aatgaagaaa agtcagtggt tatttactga gtgatctct g tcLttgcctg tcacacacac
-394 acacacacac acacaca

c ac:acacacac actgttggca gt

SSE

catttt gcaatcatct tttcaggaga gatagccctt tcggagctga aggtcaggaa

retinoid

-294 aagccagaga tttatatact tggaagtgtc gtgtttccca ggactcagaa tgacttcagc ccagaaagca gctgaagggg ttaacgtggg gacttggctg
-194 gctgtcagtt aaactttttc cctggctctg ggtttcccct tgaagggatt tccctccgcc tctctagcaa gaccct

SSE

·-94 cactcacacc agcccggctg gctttggagg ctgaacactt ttcc cagaca cttt

SSE

agagc aga
TATA

SSE

--...

tttctattt

ggcacaaa gaaggctttg aagcag ag,3.C ttgaaatgcc

E Sox retinoid

SSE

tgtgaagatg gtcgcggt.ct tgggagcctc aacggtactt tggatactgt ttgcagt.ct g taagttcctg acctatttca cacatctaca gcttctggtg

SSE

SSE

106 tactacagag ctttgctata agagccagta ttctgacaga gctggggacg gattttcttt ccactgtcaa atgagtaatt tggattatat cggtagtggg
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Whole embryo culture (WEe)

WEC was performed as previously described (Hertig et aI., 1999). Embryos at
E11.5 were removed from the uterus then dissected to leave the embryo attached to the
placenta and yolk sac via the two pairs of umbilical vessels. The embryos were placed
into roller culture bottles containing pre-equilibrated 50% DMEM and 50% immediately
centrifuged rat serum (lCRS) and cultured at 37°C with 95% O2 and 5% CO 2 . Following
a 1 hour pre-equilibration period, TGFf32 (1 Ong/ml), 9-cisRA (1 OOnM), diluent or TGFf32
(1 Ong/ml)+9-cisRA (1 OOnM) was added directly to the culture medium. Embryos were
grown in culture for 12 to 18 hours. After treatment, embryos were fixed in 2%
paraformaldehyde for 1 hour at RT, embedded in paraffin and sectioned at

7~m

to

analyze epicardial and ventricular phenotypes (using H&E staining) and
immunohistochemical analysis. Immunohistochemical analysis was performed as
described above using antibodies for VCAM-1 and a4 integrin.

Epicardial explant culture

Ventricles were dissected from E11.5 or older embryos with removal of the atria,
outflow tract and atrioventricular cushions. The ventricles were cut in half so that each
half included part of the right and left ventricle (Le. bisected in the coronal plane). The
ventricular pieces were placed epicardium side down on a fibronectin-coated 4-chamber
glass slide (Nunc). Enough media was removed to create a meniscus to hold the
ventricular pieces in place to allow the epicardium to attach to the FN-coated glass slide
overnight. The following day, fresh media was added to each well and the myocardium
was carefully removed from the epicardium leaving a lawn of epicardial cells attached to
the slide. The following day, explants were treated with TGFf32 (10ng/ml), 9-cisRA
(100nM), diluent or TGFf32 (1 Ong/ml)+9-cisRA (1 OOnM) in serum-free media for 24
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hours. Epicardial explants were then fixed for 10 minutes with 2% paraformaldehyde
and rinsed with PBS following treatment. Explants were then immunostained for rat antiVCAM-1 M/K2 (Santa Cruz) by first incubating in blocking buffer containing 1x PBS with
1% BSA and 0.3% Triton X-1 00 for 2 hours. Anti-VCAM-1 M/K2 was diluted 1:50 in 1%
BSA in 1x PBS and incubated overnight at 4°C. The following day, the slides were
washed with 1x PBS 3 times for 5 minutes each. Goat anti-rat secondary antibody
conjugated to Alexa488 (Molecular Probes) was diluted in 1x PBS at a 1: 100
concentration and incubated with the slides for 2 hours at room temperature. The slides
were washed with 1x PBS and coverslipped using Vectashield mounting media
containing DAPI nuclear stain (Vector Laboratories, Inc, Burlingame, CA). Explants
were viewed and photographed on a Zeiss AXIO M2 fluorescent microscope.
Quantification was performed using ImageJ software and the mean gray value for
representative cells from each explant was found. Images were converted to gray scale
and the antibody staining was seen as white pixels. The mean gray value represents
the intensity of white pixels present in the sample, with a higher mean gray value
indicating a higher level of expression. Statistics were calculated using a paired T-test.

VCAM-1-luciferase plasmid

Several attempts to generate the reported VCAM-1 promoter were made
following the published protocol from Hosking et al. (2004) while simultaneously
respectfully asking the authors to obtain an aliquot from the same lab (Dr. Muscat,
Australia). After a long process of clearing the Material Transfer Agreement and Dr
Muscat tracking down the plasmid for us (many months had passed) the plasmid was
finally shipped to us. The plasmid contains the full-length VCAM-1 promoter inserted
into the pGL2B-basic (pGL2B-Promega), which contains a luciferase reporter gene and
ampicillin resistance gene (Figure 15). This plasmid is promoter-less until a promoter is
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inserted into it indicating that any expression of luciferase seen is due to activation of the
inserted promoter (i.e. VCAM-1).
The primers used to make the VCAM-1 luciferase plasmid (VC1889) were as
follows (Hosking et aI., 2004) and were also used to verify plasmid identity via PCR and
direct sequencing:
1895 VCAM:

GCCGGTACCGATCTACATAGCCACGGAGAG

19 VCAM:

CGACCATCTTCACAGGCATTT

1887 KPN1 VCAM:

CGGGGTACCATAGCCACGGAGAGTTCTT

1XH01VCAM:

GCCCTCGAGTTCAAGTCTCTGCTTCAAAGCC

GLprimer 1:

TGTATCTTATGGTACTGTAACTG

GLprimer 2:

CTTTATGTTTTTGGCGTCTTCCA

These primers were used to verify that we had the correct plasmid (Figure 16) following
amplification of the plasmid using Escherichia coli (E. coli). We also performed a
restriction digest using Kpnl and Xhol to remove the VCAM-1 promoter insert from the
plasmid as another means of plasmid identity verification.
The plasmid was eluted from the filter paper in a 1.5 ml eppendorf tube
containing 100

~I

of sterile filtered 1x PBS. The filter paper was incubated in 1x PBS

overnight at 4°C. The CMV-Renilla luciferase plasmid was obtained from Promega and
was used as an internal transfection efficiency control to normalize the luciferase data.
Empty pGL2B-basic plasmid was used as a negative control. All plasmid DNA was
transformed into OneShot Mach1 chemically competent E. coli cells (Invitrogen) per
manufacturer's protocol. Transformed bacteria cells were grown on LB agar plates
containing ampicillin at 37°C. Single colonies were selected and grown in small cultures
for MiniPrep (Qiagen) to verify that we had the correct plasm ids. When the plasm ids
were confirmed by sequencing, PCR and restriction digest, we grew the transformed
bacteria in a large culture (500 ml) for MaxiPrep (Qiagen) to obtain a large amount of
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Figure 15: Diagram of the mouse VCAM-1 promoter luciferase plasmid. A schematic
diagram of the 1889 base pair portion of the mouse VCAM-1 promoter construct cloned
into the pGLBasic luciferase reporter plasmid. Luc, luciferase reporter gene; F1 ori,
origin of replication; Amp, ampicillin resistance gene. (Hosking et aI., 2004)
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Figure 16: VC1889 plasmid restriction digest and VCAM-1 promoter PCR. A. The
VC1889 luciferase plasmid was digested (lane 3) to verify the plasmid integrity. Digest
with Kpn1 and Xh01 releases the VCAM-1 promoter element, which is 1889 basepairs.
B. PCR with the GL primers (plasmid-specific, lane 2) and VCAM-1 restriction enzyme
primers (specific to the inserted VCAM-1 plasmid, lane 6) also confirm a band at
approximately 1889 basepairs. The empty plasmid (pGLBasic, lanes 3, 5 and 7) shows
no bands from the PCR indicating that the VCAM-1 promoter is not present. PCR with
the VCAM-1 primers is negative for the presence of the 1889 basepair product (lane 4),
which is expected. In order to insert the VCAM-1 promoter sequence into the plasmid,
restriction enzyme sites were inserted on the ends of the VCAM-1 promoter where these
primers (VCAM1 promoter primers) would normally bind.
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6

7

8

plasmid for transfection. Both the MiniPrep and MaxiPrep were performed via the
manufactu rer's recommendations.
In order to confirm that we had the correct VCAM-1-luciferase plasmid we
performed a restriction digest at 37°C using the restriction enzymes Kpn1 (NEB) and
Xh01 (NEB) to cut out the VCAM-1 promoter. The digest was run on a 2%) agarose gel
and can be seen in Figure 16. We also used PCR analysis to confirm that we had the
correct plasmid using the primers above that were specific to the plasmid (GL primers),
the promoter without restriction sites (1895 VCAM and 19 VCAM) and the promoter
containing the restriction sites (1887 KPN1 VCAM and 1XH01 VCAM) (Figure 16). The
primers 1895 VCAM and 19 VCAM should not have produced a band if the restriction
sites used for cloning into the plasmid were present, which can be seen in Figure 16.
Sequencing was also used to verify that we had the correct plasmid. The VCAM-1luciferase and CMV-Renilla luciferase plasm ids were then used for assays.

VCAM-1-Luciferase analysis
Following passaging, 35 mm dishes were seeded with 100,000 REC cells. The
dishes were grown to 750/0 confluency prior to transfection. The cells were transfected
with 0.25

~g

of VCAM-1-luciferase plasmid and 0.25

~g

of CMV-Renilla luciferase

plasmid. Western blot analysis was used to determine the optimal amount of plasmid to
use for transfection using a luciferase antibody to measure the production of luciferase
(Figure 17). For experiments, negative control cells were transfected with 0.25
pGL2B-basic and 0.25

~g

~g

of

of CMV-Renilla luciferase plasmid. Twenty-four hours

following transfection, the cells were treated with the indicated concentrations of TGF~2
and/or 9-cisRA. Treatments were added directly to the dishes without changing the
media from transfection. Twenty-four hours following treatment, the cells were
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Figure 17: Western blot of luciferase protein following transfection with VC1889.
Detergent extracts of REC cells transfected with different concentrations (O.25JlQ, O.5JlQ
and 1Jl9) of VC 1889 plasmid were assayed for the presence of luciferase protein in
order to determine the appropriate concentration to use for experiments. The 0.25 !-t9
transfection (lane 3) is the only one that produced luciferase and thus was the
concentration used for experiments. Lanes 1 and 2 were negative controls.
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harvested using Passive Lysis Buffer (Millipore) diluted to 1x concentration. Each dish
was washed with 1x PBS, followed by addition of 200

~I

of 1x Passive Lysis Buffer.

Each dish was scraped with a cell scraper and the buffer was transferred to a 1.5 ml
eppendorf tube. Each sample was subjected to one freeze-thaw cycle prior to assaying
for luciferase activity. Luciferase activity was analyzed using the DualGlo luciferase
assay kit (Promega) per the manufacturer's recommendations using a luminometer.
Each experiment was performed in triplicate. Statistics were calculated using a paired
T-test between each treatment group.
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Chapter 3: Results and Discussion

A. Expression patterns of VCAM-1 in RXRa-/- at E9.5 and E10.5 are similar to WT
The expression ofVCAM-1 was assessed using immunohistochemical analysis
of paraffin embedded sections of wr and RXRa-/- embryos. At E9.5, VCAM-1 protein
was expressed throughout the myocardium (Figure 18). VCAM-1 was expressed in the
PE but at levels lower than those seen in the atrial and ventricular myocardium in both
WT and RXRu-/- (Figure 18). Expression of VCAM-1 was also seen in budding PE cells
as well as migrating PE cells moving to the myocardial surface in both the

wr and

RXRa-/- (Figure 18). There were no detectable differences seen in the expression
patterns of VCAM-1 between

wr and RXRa-/- in any area of the heart at E9.S.

Previous studies by others have shown that VCAM-1 is expressed in the PE and
myocardium at this stage of mouse development (Yang et aI., 1995) hence our results in
the

wr are consistent with other published results.

integrin a4 between

No differences in expression of

wr and RXRu-/- were observed (Figure 19 and Jenkins and

Kubalak, unpublished). Both VCAM-1 and integrin a4 are necessary for PE bud
formation as well as initial PE cell attachment to the myocardium for epicardium
formation. Since the epicardium will form in the RXRa-/- mouse heart, it is not surprising
for VCAM-1 and integrin a4 levels to be similar between WT and RXRu-/-.
expressed in the PE (Molin et aI., 2003) and

TGF~2

TGF~2

is

mRNA is elevated in RXRu-/- PE

(Jenkins and Kubalak, unpublished). At this age the signaling from TGFf32 may not be
elevated enough to affect VCAM-1 levels. However, no quantitative studies of VCAM-1
expression at E9.5 have been performed (Le. real time PCR or western blot).

7S

At E1 0.5, VCAM-1 was expressed throughout the atrial and ventricular
myocardium and can be found in body wall of both the WT and RXRu-/-. VCAM-1
expression was not observed in the endocardium of WT and RXRu-/- or in the
epicardium of the WT (Figure 20), which is consistent with the current established
expression pattern of VCAM-1 in the heart (Yang et al., 1995). There were few
epicardial cells present on the myocardium in the RXRu-/- heart as is common with this
mouse due to the delay in epicardium formation (Jenkins et aI., 2005) and there was no
expression of VCAM-1 in the few epicardial cells present (Figure 20). Upon gross
examination of the embryos at E1 0.5, there were no detectable differences in the
histological phenotype of the hearts between WT and RXRu-/- mice. At E1 0.5 in
development, the RXRu-/- mouse heart begins to exhibit phenotypic differences from the

wr, with delayed epicardium formation observed and fewer PE buds present.

A change

in VCAM-1 could decrease PE bud formation, which would result in a delay in
epicardium formation. Since analysis of VCAM-1 has only been done through
immunohistochemistry at this age and at E9.5, it could be that there are some slight
differences in VCAM-1 not observable through this method. Small changes in protein
levels in embryonic development can have large consequences to the embryo. It is
possible that a slight increase or decrease in VCAM-1 is present but cannot be found
from our current experimental analysis.
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Figure 18: IHe analysis of VCAM-1 expression at E9.5 in the WT and RXRa-/- mouse
heart. VCAM-1 expression (green) is seen in the PE, PE buds and ventricular
myocardium in hearts from both
(8 and C) and RXRa-/- (E and F). No histological
abnormalities were apparent in the hearts of E9.5 RXRa-/- (D) as compared to the wr
(A). The arrow indicates PE buds that are migrating to the surface of the myocardium.
Atr, atrium; Vent, ventricle; PE, proepicardium. Green- VCAM-1; Blue- ToPro3 nuclear
stain. Images are representative of two experiments (2 litters) each having
immunostained sections from the hearts of one WT and one RXRa-/- embryo from the
same litter.
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Figure 19: IHe analysis of integrin a4 subunit expression at E9.S and E10.S in the wr
and RXRa-/- mouse heart. Integrin a4 subunits expression (green) is seen in the PE
and myocardium of the WT (A) and RXRa-/- (8) at E9.S. Integrin a4 expression is seen
in the epicardium and myocardium of the WT (C) and RXRa-/- (0) at E1 0.5. BW, body
wall; PE, proepicardium; Myo, myocardium; Endo , endocardium; Epi, epicardium.
Green- integrin a4; Blue- ToPro3 nuclear stain. Images are representative of two
experiments (2 litters from each stage) each having immunostained sections from the
hearts of one WT and one RXRa-/- embryo from the same litter.
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Figure 20: IHC analysis of VCAM-1 expression at E1 0.5 in the WT and RXRa-/- mouse
heart. VCAM-1 (green) is expressed in the myocardium and body wall in both the WT (8
and C) and RXRa-/- (E and F). The ventricular myocardium in the RXRa-/- mouse heart
is thinner (0) than the ventricular myocardium in the WT (A). Boxed area in A is found in
panels Band C. Boxed area in D is found in E and F. Myo, myocardium; Epi,
epicardium; Atr, atrium; OFT, outflow tract; AV, atrioventricular junction; Vent, ventricle.
Green- VCAM-1; Blue- ToPro3 nuclear stain. Images are representative of two
experiments (2 litters) each having immunostained sections from the hearts of one WT
and one RXRa-/- em bryo from the same litter.
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B. TEM of WT and RXRa-/- hearts at E10.5
From previous studies of the RXRa-/- mouse, there is a delay in formation of the
epicardium in the RXRa-/- mouse (approximately 0.5-1.0 day later than Wf) and, once
formed, will be detached from the myocardium at E12.5 when the epicardium is normally
closely associated with the underlying myocardium. Clearly, there must be an initial
attachment of proepicardial buds that allows the epicardium to form in the mutant. This
is in contrast to what was found in the in the integrin a4 and VCAM-1 KOs where a lack
of attachment prevents the formation of the epicardium (Kwee et aI., 1995; Yang et aI.,
1995). In the RXRa-/- mouse heart there are a few areas of the myocardium where
proepicardial cells do attach. However, since there are large areas where the
epicardium is not attached, intercellular junctions were examined at the ultrastructural
level. TEM analysis was used to examine cell junctions in more detail. In the RXRa-/mouse heart, cellular junctions were harder to find between myocytes and epicardial
cells as shown in Figure 21. However, cell junctions between adjacent epicardial cells
were readily visible, therefore defects in detachment are most likely between epicardium
and myocardium and not between adjacent epicardial cells (Figure 21). This is not
surprising because there is a complete epicardium that forms in the RXRa-/- mouse
heart, indicating that the epicardial cells will attach to each other however fail to remain
attached to the myocardium.
Also evident in the micrographs of the RXRa-/- mouse heart was the decrease in
visible mitochondria as well as free ribosomes (Figure 21). This is also not surprising
because it has been previously reported that the RXRa-/- mice have metabolic
deficiencies in addition to heart defects (Ruiz-Lozano et aI., 1998). Data from this paper,
however, reported an increased density of mitochondria per cell possibly as a feedback
mechanism responding to the decreased metabolic state (Ruiz-Lozano et aI., 1998).
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Figure 21: Immunogold TEM analysis of epicardium/myocardium junctions in E1 0.5 WT
and RXRa-/- mouse hearts. The WT epicardium/myocardium junction (A) has a visible
cell junction and immunogold-Iabelled FN (black dots) present in the subepicardial
space. The epicardial cell junction also has a well-defined junction (8). The RXRa-/epicardium/myocardium junction has a less well-defined cell junction (C) than the WT
(A). Immunogold-Iabelled FN is also present in the subepicardial space (black dots in
C). The cell junction between epicardial cells is well defined (D). Epi, epicardium; Myo,
myocardium; FN, fibronectin; Mit, mitochondria
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This observation in E12.5 embryos was not statistically significant (Ruiz-Lozano et aI.,
1998). It is possible that from E1 0.5 (fewer mitochondria) to E13.5 (more mitochondria)
the heart is trying to make up for the metabolic deficiencies by producing more
mitochondria. However, since metabolic deficiencies still exist at E13.5, the increase in
mitochondria does not completely restore function.

c. VCAM-1

is misexpressed in the epicardium of the RXRa-l- mouse heart at E11.S

Examining embryos just prior to full epicardial attachment at E11.S, VCAM-1 was
expressed throughout the atrial and ventricular myocardium and not in the endocardium
of both the WT and RXRa-/- as shown by immunohistochemistry (Figure 22). VCAM-1
was not expressed in the epicardium of the WT but was, however, expressed in the
epicardium of the RXRu-/- mouse (Figure 22). Others have shown that VCAM-1 is not
expressed in the epicardium and is expressed only in the myocardium of the heart
(Kwee et ai, 1995). Expression of VCAM-1 in the epicardium has not been reported
previously in any mouse model and represents a novel finding in heart development.
Currently the role of misexpression of VCAM-1 in the epicardium of the RXRa-/- mouse
is not known but it is speculated that it could adversely affect cell-cell adhesion between
the epicardium and myocardium as well as interfere with epicardial EMT. Indeed, the

RXRa-/- mouse has been previously reported to have fewer epicardial-derived cells in
the heart (Merki et aI., 2005) and VCAM-1 has been shown to negatively affect EMT
(Ookic and Dettman, 2006). Together, these results suggest that VCAM-1 may playa
role not only in the apparent defective cell adhesion found in the mutant but also the
blunted EMT observed in the RXRu-/- mouse epicardium (Ruiz-Lozano and Kubalak,
unpublished), which will be discussed further in Chapter 4.
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Figure 22: IHC analysis of VCAM-1 expression in hearts of E11.S in the WT and RXRu-/mice. The WT mouse has expression ofVCAM-1 in the myocardium but not in the
endocardium or epicardium (B-E). The RXRu-/- mouse heart has expression of VCAM-1
in the myocardium and also in the epicardium (G-J). AV, atrioventricular junction; RV,
right ventricle; LV, left ventricle; Myo, myocardium; Endo, endocardium; Epi, epicardium;
BW, body wall. Green- VCAM-1; Blue- ToPro3 nuclear stain. Images are representative
of three experiments (3 litters) each having immunostained sections from the hearts of
one
and one RXRu-/- embryo from the same litter.
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In order to get a more quantitative measure of VCAM-1 levels, real time PCR
analysis of RNA from E11.5 whole hearts was perform·ed. An increase in VCAM-1
mRNA was observed at E11.5 in the RXRa-/- mouse heart compared to the WT (Figure
23). However, when protein levels of VCAM-1 were analyzed using Western blot
analysis of E11.5 whole hearts, no differences were found between WT and RXRa-/(Figure 24). The increased VCAM-1 mRNA might not have been translated into protein
at the time of the assay. In the RXRu-/- mouse heart there is an increase in MLC2a
mRNA observed (Dyson et aI., 1995) without an increase in protein level (Kubalak et aI.,
2002) so it is plausible that VCAM-1 mRNA could be increased without an increase in
protein. The misexpressed VCAM-1 protein at E11.5 appeared to be localized to the
epicardium and was perhaps not significant enough to detect in whole heart. At this time
it is not entirely known what the consequence are of having VCAM-1 expression in the
epicardium. Altering the normal expression pattern of a cellular adhesion molecule
might have a negative impact on epicardial cell adhesion or may have more significant
effect on epicardium function such affecting epicardial EMT. VCAM-1 has been shown
to negatively affect epicardial EMT (Dokic and Dettman, 2006). Soluble VCAM-1
treatments increased the association of E-cadherin and

~-catenin

in cellular junctions

thereby decreasing epicardial EMT (Dokic and Dettman, 2006). So it is possible that
misexpressed VCAM-1 in the epicardium is strengthening epicardial cell adhesion and
decreasing EMT.
No apparent differences in integrin a4 protein were seen from
immunohistochemical analysis (Figure 25) between E11.5 WT and RXRu-/-. However
preliminary studies using real time peR analysis suggested there may be an increase in
integrin a4 mRNA in the RXRa-/- mouse heart in comparison to the WT heart (Figure
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Figure 23: Real time PCR analysis of VCAM-1 mRNA in hearts of E11.5 in wr and
RXRu-/- mice. Levels of mRNA are represented as a fold change from WT using the
comparative Ct method. The mRNA from E11.5 RXRu-/- whole heart have
approximately 2.75 fold higher level of VCAM-1 mRNA as compared to the average of
the WT samples. The error bar represents ± standard error of the mean (SEM). The
plotted values are mean fold change from the WT values. This experiment was
performed in triplicate on two pairs of WT and RXRa-/- whole hearts.
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Figure 24: Western blot analysis of VCAM-1 protein in E11.5 in wr and RXRu-/- hearts.
There was no statistically significant difference in VCAM-1 protein levels between wr
and RXRu-/-. Protein levels are represented as fold change from the average of the wr
samples. The plotted values represent the mean fold change from wr of three
experiments performed on a wr and RXRu-/- pair from the same litter (3 litters total).
The error bar represents ± SEM. A representative blot is shown.
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Figure 26: Real time PCR analysis of N-cadherin, integrin a4 subunit and TGF~2 at
E11.5 in the WT and RXRa-/- heart. All mRNA levels are represented as a fold change
from the WT using the comparative Ct method. N-cadherin is no different between WT
and RXRa-/-. Integrin a4 appears to have higher mRNA levels in the RXRa-/- mouse
heart than the WT. TGF~2 mRNA levels are higher in the RXRa-/- mouse heart than in
the WT. This experiment was performed in triplicate on one WT and one RXRa-/- each
from the same litter. Error bars represent the range of values for the triplicates.
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26). No difference in the mRNA expression of N-cadherin was seen between E11.5

wr

and RXRa-/- (Figure 26). Increased TGF(32 mRNA was found in the RXRa-/- mouse
heart in comparison to the

wr which served as a positive control and is consistent with

our previous finding of increased TGF(32 mRNA in the RXRa-/- heart during
midgestation (Kubalak et aI., 2002). This preliminary real time experiment (n=1) would
need to be repeated prior to drawing any major conclusions from these results.

D. VCAM-1 expression is increased in RXRa-l- hearts at E12.5 and E13.5

At E12.5, the epicardium is normally in close association with the myocardium.
EMT is altered in the RXRa-/- epicardium, as shown from previous studies with this
mouse model (Ruiz-Lozano and Kubalak, unpublished), so it is possible that the
disassociation of the epicardium from the myocardium (Le., epicardial bubbling) is
negatively impacting EMT. Relatively low levels of VCAM-1 were expressed in the
E12.5 myocardium of both the WT and RXRa-/- and none was detected in the
endocardium at E12.5 (Figure 27) or at E13.5 (Figure 28). VCAM-1 was also not
expressed in the endocardial cushions of the AV or OFT (data not shown). The
misexpression of VCAM-1 found in the E11.5 RXRa-/- epicardium was also found in the
E12.5 and E13.5 RXRa-/- epicardium. No VCAM-1 expression was seen in the

wr

epicardium at either age (Figures 27 and 28). Analysis of VCAM-1 mRNA expression
using real time PCR showed that VCAM-1 mRNA was elevated in the RXRa-/- heart at
both E12.5 (Figure 29) and E13.5 (Figure 30) in comparison to the WT. When protein
levels in the E12.5 and E13.5 WT and RXRa-/- heart were analyzed using Western blot
analysis, higher levels ofVCAM-1 protein were seen at both E12.5 (Figure 31) and
E13.5 (Figure 32) RXRa-J- than in WT. At E11.5, the epicardium is normally dissociated
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Figure 27: IHC analysis ofVCAM-1 expression at E12.S in the WT and RXRa-/- heart.
VCAM-1 is expressed in the myocardium but not the epicardium or endocardium of the
WT heart (B-E). VCAM-1 is expressed in the myocardium at higher levels in the RXRa/- mouse (G-J) than the WT. VCAM-1 is also expressed in the epicardium in the RXRa/- mouse (G-J). H&E sections of the WT (A) and RXRa-/- (F). Bubbling of the
epicardium can be seen in the RXRa-/- mouse (G-J). RA, right atrium; OFT, outflow
tract; AV, atrioventricular junction; LV, left ventricle; RV, right ventricle; Epi, epicardium;
Myo, myocardium; Endo, endocardium. Green- VCAM-1; Blue- ToPro3 nuclear stain.
Images are representative of three experiments (3 litters) each having immunostained
sections from the hearts of one WT and one RXRa-/- embryo from the same litter.
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Figure 28: IHC analysis of VCAM-1 expression at E13.5 in the WT and RXRa-/- heart.
VCAM-1 is expressed in the myocardium but not the epicardium or endocardium of the
V\fT heart (B-E). VCAM-1 is expressed in the myocardium at higher levels in the RXRa/- mouse (G-J) than the WT. VCAM-1 is also expressed in the epicardium in the RXRa/- mouse (G-J). H&E sections of the WT (A) and RXRa-/- (F). Bubbling of the
epicardium can be seen in the RXRa-/- mouse (G-J). RA, right atrium; LA, left atrium;
AV, atrioventricular junction; LV, left ventricle; RV, right ventricle; Epi, epicardium; Myo,
myocardium; Endo, endocardium. Green- VCAM-1; Blue- ToPro3 nuclear stain. Images
are representative of three experiments (3 litters) each having immunostained sections
from the hearts of one WT and one RXRa-/- embryo from the same litter.
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Figure 29: Real time PCR analysis ofVCAM-1 mRNA at E12.S in WT and RXRa-/heart. VCAM-1 mRNA levels are almost 5-fold higher in the RXRa-/- mouse heart than
in the WT. Values are expressed as a fold difference from WT using the comparative Ct
method. The error bar represents ± standard error of the mean (SEM). The plotted
values are mean fold change from the WT values. This experiment was performed in
triplicate on two pairs of WT and RXRa-/- whole hearts.
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Figure 30: Real time PCR analysis of VCAM-1 mRNA at E13.5 in WT and RXRa-/heart. VCAM-1 mRNA leyels are approximately 8.5-fold higher in the RXRa-/- mouse
heart than in the WT. Values are expressed as a fold difference from WT using the
comparative Ct method. This experiment is representative of one pair of WT and RXRa/- whole heart mRNA samples performed with three replicates. Error bars represent the
± SEM of the triplicates
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Figure 31: Western blot analysis VCAM-1 protein at E12.5 in the WT and RXRu-/- heart.
VCAM-1 protein levels are elevated in the RXRu-/- mouse heart in comparison to the
wr whole heart. The plotted values represent the mean fold change from WT of three
experiments performed on a WT and RXRu-/- pair from the same litter (3 litters total).
The error bar represents ± SEM. A representative blot is shown.
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Figure 32: Western blot analysis of VCAM-1 protein at E13.5 in the 'NT and RXRa-/hearts. VCAM-1 protein levels are elevated in the RXRa-/- mouse heart in comparison to
the 'NT whole heart. The graph shows the quantification of the western blot performed
on one WT and one RXRa-/- each from the same litter.
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Figure 33: Real time PCR analysis of N-cadherin, integrin a4 and TGF~2 in E12.S \NT
and RXRa-/- heart. All mRNA levels are represented as a fold change from the \NT
using the comparative Ct method. N-cadherin is lower in the RXRa-/- mouse heart than
\NT. Integrin a4 has lower mRNA levels in the RXRa-/- mouse heart than the WT.
TGF~2 mRNA levels are higher in the RXRa-/- mouse heart than in the WT. The plotted
values are the means of the triplicates from the experiment using one WT and one
RXRa-/- heart from the same litter. Error bars represent the range of values for the
triplicates.
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from the myocardium in the WT heart. However, at E12.5 the epicardium is normally
attached and closely associated with the myocardium. From E11.5 to E12.5 there is an
increase in VCAM-1 protein that occurs suggesting that VCAM-1 could playa role in this
detached epicardial phenotype. Epicardial EMT is also occurring at E12.5 when VCAM1 protein is increased so VCAM-1 may playa role in inhibiting epicardial EMT. The
RXRa-/- mouse has decreased epicardial EMT (Ruiz-Lozano and Kubalak, unpublished)
and VCAM-1 has been shown to negatively affect epicardial EMT (Dokic and Dettman,
2006).
No differences were observed in integrin a4 protein expression at E12.5 (Figure
25) or E13.5 in preliminary experiments (data not shown). When mRNA levels of
integrin a4 at E12.5 were examined, a lower level of integrin a4 mRNA was seen in the
RXRa-/- mouse heart than in the WT (Figure 33). This is in contrast to what was
observed at E11.5 where there appeared to be a higher level of integrin a4 in the
RXRa-/- heart in comparison to the WT. The result at E12.S will need to be repeated
prior to making any definitive conclusions. When N-cadherin was analyzed, there was a
lower level of mRNA in the RXRa-/- mouse heart than in the WT at E12.S (Figure 33).
At E11.5 there was a slight decrease in N-cadherin mRNA in the RXRa-/- heart (Figure
26). The N-cadherin knockout is known to have a detached epicardium (Luo et aI.,
2006). However, before any conclusions can be made on the role of N-cadherin in the
phenotype of the RXRa-/- mouse, real time experiments would need to be repeated and
protein levels would also need to be examined. Levels of TGF(32 mRNA were examined
as a positive control and an increase in TGFf32 mRNA was found in the RXRa-/- heart
(Figure 33), which is consistent with our findings at midgestation (Kubalak et aI., 2002).
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E. Epicardial explants from E13.5 RXRa-/- have a higher level of VCAM-1 than WT
In order to provide further evidence that there was indeed aberrant expression of
VCAM-1 in the epicardium of the RXRa-/- mouse, epicardial explants were grown in
culture from a

wr and RXRci-/- heart.

The ventricular pieces were placed epicardium

side down on a FN-coated glass slide as described in Chapter 2 and, after removing
myocardial tissue, allowed to grow for 2 days prior to fixation with 2% paraformaldehyde.
The explants were then immunostained for VCAM-1. In both the WT and RXRa-/explants, epicardial cells expressed VCAM-1 (Figure 34). However, levels of VCAM-1
were higher in the RXRa-/- epicardial cells than in the

wr.

The higher levels present in

the RXRa-/- cells is consistent with our previous findings that VCAM-1 is misexpressed
in the epicardium prior to explant culture. The RXRa-/- epicardial explants were already
expressing VCAM-1 prior to being explants and, therefore, retain higher levels of VCAM1 in culture. The expression of VCAM-1 in the

wr epicardial

explants was surprising

since VCAM-1 is not typically expressed in the epicardium. This expression would
indicate that epicardial cells are intrinsically capable of expressing VCAM-1 but do not
under normal physiological conditions. When the epicardial cells are placed into an
artificial culture system, the signaling that typically occurs in the epicardium could be
altered resulting in VCAM-1 expression. Epicardial explants are grown on FN-coated
slides. Since binding of FN by integrin a4 can induce several signaling cascades,
excess FN/integrin a4 binding could induce signaling changes that induce VCAM-1
expression.

F. Smad and retinoid elements are located within the VCAM-1 promoter
The VCAM-1 promoter sequence was analyzed using the Transcription Element
Search System (TESS) (http://www.cbil.upenn.edu/cgi-bin/tess/tess) to locate putative
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Figure 34: IHC analysis of VCAM-1 protein expression in E13.5 RXRa-/- epicardial
explants than Wf. Epicardial explants from RXRa-/- had a higher level of VCAM-1 (D-F)
than the Wf (A-C). Green- VCAM-1; Blue- Dapi nuclear stain. This experiment was
performed on epicardial explants from one wr and one RXRa-/- mouse from the same
litter.
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binding sites for RXRa and Smads to determine if the retinoid and/or TGFj32 signaling
pathways might regulate VCAM-1. This was followed by a manual search throughout
the sequence using the consensus sequence for the binding sites. From this search
several Smad binding elements (SBEs) and retinoid responsive elements were located
in the VCAM-1 promoter (Figure 14). One of the pairs of retinoid elements is in a DR6
direct repeat configuration for binding of a RAR/RXR heterodimer (Figure 14). Both 9cisRA and at-RA are predicted to activate this heterodimer. There are several retinoid
elements present on the promoter that are not paired with another retinoid element
(Figure 14). These elements on the promoter might be used as binding sites for any of
the other receptors that RXRa is known to heterodimerize with including the vitamin D
receptor, thyroid hormone receptor and PPARs.

G. RXRa and Smad4 will bind to the VCAM-1 promoter
Since potential Smad and retinoid elements have been located on the VCAM-1
promoter, we wanted to determine if it was possible for RXRa or Smads to bind to the
VCAM-1 promoter. ChiP analysis was used to determine if either RXRa or Smad4 were
capable of binding to the VCAM-1 promoter. In order for either RXRa or Smads to
directly regulate VCAM-1 expression, they must be able to bind to the promoter. This
would also validate the in silica promoter analysis which suggests that there are binding
sites for both RXRa and Smads. The negative control (no immunoprecipitating antibody)
was negative for bands from the VCAM-1 PCR (Figure 35, lane 6) and control PCR for
the GAPDH promoter (Figure 35, lane 2). The positive control for immunoprecipitation
was the RNA polymerase antibody followed by PCR for the GAPDH promoter (Figure
35, lane 4).

117

Figure 35: Chromatin immunoprecipitation analysis showing that RXRa and Smad4 bind
to the VCAM-1 promoter. Chromatin immunoprecipitation shows RXRa and Smad4
binding to VCAM-1 promoter. ChiP using the negative control (no antibody) shows no
amplicons corresponding to GAPDH in the control PCR (lane 2) or for VCAM-1 promoter
(lane 6). RNA polymerase immunoprecipitating antibody followed by PCR for GAPDH
was used a positive control (lane 4). The VCAM-1 promoter band is observed in the
samples using RXRa immunoprecipitating antibody (lane 8) and Smad4
immunoprecipitating antibody (lane 10). The input samples contain genomic DNA that
was added to the immunoprecipitating antibody for the experiment (lanes 3, 5, 7, 9, 11)
and were positive controls. Lane 1 is a 1 kilobase ladder and lane 12 is a no DNA
control performed to confirm specificity of the PCR reaction.
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RXRa was found to be capable of interacting with the VCAM-1 promoter. The RXRa
antibody bound to RXRa located on DNA fragments of the VCAM-1 promoter and
immunoprecipitated the VCAM-1 promoter as was indicated by the band seen following
PCR with the VCAM-1 promoter primers (Figure 35, lane 8). No band would have been
present following PCR if RXRa did not immunoprecipitate the VCAM-1 promoter. The
DNA that was used in the experiments (the input- inp) also showed a band for the
VCAM-1 PCR as was to be expected because it was the positive control containing all
genomic DNA (Figure 35, lane 9). Currently, it is not known which of the retinoid sites
RXRa is binding to or if RXRa is binding as a homodimer (RXRa/RXRa) or a
heterodimer with another retinoid receptor or related receptor (RARs, other RXRs,
Vitamin 0, PPAR).
Smad4 was capable of binding to the VCAM-1 promoter as was indicated by the
band seen in PCR for the VCAM-1 promoter (Figure 35, lane 10). The input sample also
had a band from the VCAM-1 PCR (Figure 35, lane 11). Since Smad4 is a common
Smad shared by multiple pathways, binding would indicate activation by any of the TGF(3
isoforms, activin or BMPs. Our hypothesis is that

TGF~2

is primarily responsible for

activation of VCAM-1 given that there is an increase in TGFf32 in the RXRa-/- heart
coupled with an increase in VCAM-1. The following sets of experiments tested the
hypothesis that TGFf32 could increase the expression of VCAM-1. In order to determine
which retinoid or Smad binding sites are responsible for regulating the VCAM-1
promoter, mutational analysis of the promoter would need to be performed.

120

H. TGFp2 causes epicardial bubbling and induces VCAM-1 expression the

epicardium
Embryos at E11.S were grown in whole embryo culture and subjected to

TGF~2

(10 ng/ml) or 9-cisRA (100nM) treatments. Both TGFf32 and 9-cisRA treatments were
used because the ChiP and in silico promoter analyses indicated that RXRa and Smad4
could both bind to the VCAM-1 promoter. Treatments to activate TGFf32 and/or retinoid
signaling will help determine which pathway is likely responsible for the increase in
VCAM-1 seen in the RXRa-/- heart since both pathways are altered in the mutant.
No gross histological differences were observed between any of the 12 hour
treated embryos (Figure 36). All embryos displayed a detached epicardium and similar
thickness of the ventricular myocardium. The embryos were treated for 12 hours
beginning at E11.S in development so when the culture was stopped, the age of the
embryos was around E12. At E12 of in vivo development it is normal to have a
somewhat detached epicardium because it is not normally fully attached until E12.S.
Another possible reason that there were no gross differences between control and
treated embryonic hearts after 12 hours of culture is that the embryos were not in culture
long enough for differences to develop.
When the embryos were treated for 18 hours, histological analysis showed that
the epicardium was attached in the diluent control (Figure 37). However, TGFf32 treated
embryos displayed a detached epicardium in various regions of the heart. There
appeared to be no histological difference in the ventricular myocardium in each
treatment (Figure 37). One issue that exists with the 18 hour culture is that this time
frame represents the limits that whole mouse embryos can be cultured. Thus, the
integrity of the embryos may become compromised once they reach the E12.0-12.S age.
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Figure 36: IHC analysis of VCAM-1 expression following TGF~2 treatment in 12 hour
whole embryo culture. There appears to be no phenotypical difference between diluent
(A) and TGF~2 treatment (C) in the H&E stained paraffin sections. There are higher
levels of VCAM-1 in the TGF~2-treated embryos (0) than in the diluent (8). VCAM-1 is
expressed in the myocardium and epicardium of both the diluent (8) and TGFp2-treated
(0). Green- VCAM-1; 8lue- Dapi nuclear stain. Myo, myocardium; Epi, epicardium.
Images are representative of two experiments (2 embryos of each treatment) each
having immunostained sections from the hearts of one diluent and one TGF~2 treated
embryo.
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Figure 37: IHC analysis showing that VCAM-1 expression increases and the epicardium
detaches following 18 hours of TGF~2 treatment in whole embryo culture. VCAM-1 is
expressed in the myocardium of the diluent treated embryo (C, D, F,G) and the TGF~2treated embryo (J, K, M, N). VCAM-1 is not expressed in the epicardium of the diluenttreated embryo (C, D, F, G) but is expressed in the epicardium of the TGF~2-treated
embryo (J, K, M, N). The diluent-treated embryo has an attached epicardium (A, B, E)
but the TGF~2-treated embryo has a detached epicardium (H, I, L). Images are
representative of one experiment (one set of treatments) with immunostained sections
from the hearts of one diluent and one TGF~2 treated embryo.
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Figure 38: TGF~2 treatment of epicardial explant cultures results in increased VCAM-1
expression. wr epicardial explants were treated with diluent, TGF~2, 9-cisRA and
TGF~2+9-cisRA for 24 hours. VCAM-1 was expressed in all of the explants. However,
there is great expression of VCAM-1 in the TGFf32 (C) and TGF~2+9-cisRA (0)
treatments than in diluent (A) and 9-cisRA (8). These data were quantified in E using
ImageJ. There is a statistically significant difference between diluent and TGF~2 (*),
diluent and TGF~2+9-cisRA (*), 9-cisRA and TGF~2 (#), and 9-cisRA and TGF~2+9cisRA (#). There is no statistical significance between diluent and 9-cisRA treatment or
between TGF~2 and TGF~2+9-cisRA treatment. A representative immunohistochemical
staining is show in A-D. The plotted values in E are the mean gray value of pixels per
cell of 3 independent experiments each having a diluent, TGF~2, 9-cisRA and TGF~2+9cisRA treatment.
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Treatment with TGFf32 either alone or with 9-cisRA induced expression of VCAM-1 over
that of either diluent or 9-cisRA alone (Figure 38). These data would indicate that
TGFf32 can directly stimulate expression of VCAM-1 and that addition of 9-cisRA to the
TGFf32 treatment has no additive affect on expression (Figure 38). The
immunohistochemical data was quantified using ImageJ. Quantification of the
immunohistochemical data confirmed what was seen in the immunohistochemical
staining. Statistical significance was calculated using paired T-tests to compare each
treatment. The differences seen between the diluent, TGFf32 and TGFf32 + 9-cisRA are
statistically significant. The differences found between 9-cisRA,

TGF~2

and TGFf32 + 9-

cisRA are also statistically significant. There was no statistical significance between
diluent and 9-cisRA indicating that 9-cisRA has little to no effect on VCAM-1 expression
elevation. This finding would suggest that the retinoid binding elements on the promoter
are not functional, not responsive to 9-cisRA (not an RXR) or that the concentration of 9cisRA used did not induce receptor activation. The retinoid binding elements could be
RXR heterodimer sites meaning that the ligand for the RXR heterodimer partner would
also need to be present to activate transcription through RXR binding.

J. VCAM-1-luc activity increases with TGFp2 treatment
In order to further determine if TGFf32 was having a direct effect on VCAM-1
expression, an expression plasmid containing the VCAM-1 promoter upstream of a
luciferase reporter gene was used. Plasmid identity was confirmed by performing a
restriction digest with Xhol and Kpnl to remove the VCAM-1 promoter from the plasmid
and also by direct sequencing of the plasmid. When transcription factor binding
activates the VCAM-1 promoter, luciferase will be produced and can be quantified using
a luminometer. Luminescence gives a quantifiable response of the VCAM-1 promoter to
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TGF(32 treatment instead of a more qualitative measure used previously with explants
and WECo
Rat epicardial cells were used to analyze the VCAM-1 promoter element and
were grown as described in Chapter 2 until reaching approximately 75% confluency.
Once the appropriate confluency was reached, the cells were transfected with the
VCAM-1-luc plasmid (VC1889) and the CMV-Renilla-Iuc plasmid (control for
normalization). Following 24 hours of transfection, treatments were added to each 35
mm dish directly into the culture medium. The cells were treated with TGF(32 (10 ng/mL)
and/or 9-cisRA (100 nM). Following the 24 hours of treatment, the cells were harvested
and subjected to a luciferase assay to determine luciferase activity. Each sample was
assayed for both Firefly luciferase (VCAM-1-luc) and Renilla luciferase (CMV-ReniI1aluc). The VCAM-1-luc data were then normalized to CMV-Renilla-Iuc to account for
differences in transfection efficiency. The fold-change from the diluent treatment of
VCAM-1-luc was calculated for each treatment to compare between experiments. All
statistics were calculated from the raw data using paired T-tests to compare between
each treatment.
Treatment with TGF(32 resulted in a higher level of VCAM-1-luciferase activity
than treatment with diluent, which was statistically significant (p<0.05) (Figure 39).
There was no statistically significant difference in VCAM-1-luc activity between 9-cisRA
treatment and diluent or between either TGF(32 treatment (Figure 39). This would
indicate that RA signaling is not responsible for increasing transcription of VCAM-1. It is
possible that the retinoid sites present on the promoter could be heterodimer sites for
RXRa. to bind with another receptor (Vitamin D, PPAR) indicating that the other receptor
in the heterodimer needs to be activated to elicit an effect on VCAM-1. Further studies
with other treatments to activate those receptors are required to address this.

130

Figure 39: TGF(32 treatment of cells transfected with the VC1889 luciferase expression
plasmid increases VCAM-1-driven luciferase expression. REC cells were transfected
with the VC1889 plasmid and CMV-Renilla luciferase control plasmid. Following
treatment, cells were harvested and assayed for luciferase expression. The firefly
luciferase (VC1889) was normalized to the CMV-Renilla luciferase values. The
normalized values were then expressed as a fold change from diluent. There is a
statistically significant difference between diluent and TGF(32 (*), diluent and TGF(32+9cisRA (*), 9-cisRA and TGF(32 (#), and 9-cisRA and TGF(32+9-cisRA (#). There is no
statistical significance between diluent and 9-cisRA treatment. These results represent
8 independent experiments performed in triplicate. The plotted values are the mean fold
change from the diluent values. Error bars represent ± SEM.
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Figure 40: Concentration-response study of cells transfected with VC 1889 luciferase
expression plasmid and treated with varying TGF~2 concentrations. Treatments with
varying concentrations of TGF~2 were done on REC cells transfected with VC1889 and
CMV-Renilla. The firefly luciferase (VC 1889) was normalized to the CMV-Renilla
luciferase values. The normalized values were then expressed as a fold change from
diluent. The asterisk (*) represents statistical significance between diluent and 0.1 ng/ml
TGF~2, 2.5 ng/ml TGF~2, 5 ng/ml TGF~2 and 10 ng/ml TGF~2. These results represent
7 independent experiments performed in triplicate. The plotted values are the mean fold
change from the diluent values. Error bars represent ± SEM.
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Alternatively, the retinoid consensus sites indentified on the promoter may not be
functional retinoid binding sites.
Treatment with both TGFf32 and 9-cisRA together shows a statistically significant
increase in VCAM-Iuc activity compared to both diluent and 9-cisRA alone (Figure 39).
However, there was no statistically significant difference in VCAM-1-luc activity between
TGFf32 alone and TGFf32 plus 9-cisRA, indicating that TGFf32 does not interact with 9cisRA to have an influence on VCAM-1 expression at least not at the concentrations
used in this experiment (Figure 39).
A dose response experiment was performed to evaluate the effect of TGFf32 on
induction of VCAM-1-luc activity. An apparent biphasic response curve was observed
(Figure 40). At the lowest concentration of TGFf32 (0.1 ng/ml), there was a statistically
significant increase in VCAM-1-luc activity seen compared to diluent (Figure 40). At the
next three concentrations tested (0.25 ng/ml, 0.5 ng/ml and 1 ng/ml), there was a
decrease in the amount of VCAM-1-luc activity seen from 0.1 ng/ml treatment and there
is no statistical significance in comparison to the diluent (Figure 40). When transfected
cells are treated with the next three concentrations (2.5 ng/ml, 5 ng/ml and 10 ng/ml), the
amount of VCAM-1-luc activity increased to levels that were significantly higher (p<0.05)
as compared to the diluent treatment (Figure 40). Previous studies using different
concentrations of TGFf32 in treatment suggested that at lower concentrations of TGFf32
that p38 was being activated instead of Smads (Sauls, Hoover and Kubalak,
unpublished). The biphasic response curve in this study could represent activation of
the VCAM-1 promoter through both p38 (at lower concentrations) and Smad activation
(at higher concentrations) by TGFf32.
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Chapter 4: Conclusions and Future Directions

From this study and those of others, it is concluded that VCAM-1, a cell adhesion
molecule previously found to be necessary for epicardium formation (Kwee et aI., 1995),
is playing an integral role in the normal development of the heart following formation of
the epicardium. Appropriate levels and cell-type specific expression of VCAM-1 is
essential for normal cardiac morphogenesis including, but not limited to, the formation of
EPDCs, which will contribute to the formation of coronary vasculature, ventricular
chamber maturation and valve formation (Dettman et aI., 1998; Gittenberger-de Groot et
aI., 1998; Manner, 1999,2000; Mikawa and Fischman, 1992; Mikawa and Gourdie,
1996; Perez-Pomares et aI., 1997; Vrancken Peeters et aI., 1999). Using the RXRa-/mouse, a model of aberrant cardiac morphogenesis, alterations in VCAM-1 expression
were found. This study showed an increase in VCAM-1 mRNA and protein in the
myocardium of the RXRa-/- heart from E11.S-E13.S compared to the WT. In addition,
VCAM-1 was misexpressed in the epicardium of the RXRu-/- heart at E11.S-E13.S
compared to the WT, which normally has no VCAM-1 expression in the epicardium.
Since VCAM-1 was increased and misexpressed in the RXRa-/- heart, we wanted to
look at regulation of this gene. Retinoid and Smad-binding elements were found on the
VCAM-1 promoter (by in silica promoter analysis) and both RXRa and Smad4 were
capable of binding to the VCAM-1 promoter (shown with ChiP analysis) suggesting
regulation of VCAM-1 by retinoid and/or TGFj32 signaling. TGFj32 treatment induced
expression of VCAM-1 in epicardial explants as well as in the epicardium in whole
embryo culture while 9-cisRA treatment had no effect. Treating REC cells transfected
with VC1889 luciferase expression plasmid with TGF(32 demonstrated that TGFj32
activates the VCAM-1 promoter to induce luciferase activity while treatment with 9-cisRA
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does not activate the VCAM-1 promoter. The results from this study demonstrate that
VCAM-1 is upregulated in the RXRa-/- model of aberrant epicardium formation and that
TGFf32 is capable of upregulating VCAM-1 in the developing heart. Our current working
model of the role of normal and aberrant VCAM-1 expression is present in Figure 41.
Furthermore, these studies suggest that appropriate expression of VCAM-1 regulated by
TGF(32 is a significant contributing factor in normal heart development. The
consequences of changes in VCAM-1 expression and cell type specific location to the
developing heart are not fully known, however, several potential scenarios will be
discussed.
Integrin Involvement
Integrin 0.4 and VCAM-1 have both been previously been shown to be essential
to formation of the epicardium (Kwee et aI., 1995; Yang et aI., 1995), however, their role
in cardiac morphogenesis following epicardium formation is not fully known. Currently it
is thought that binding between integrin 0.4 (in the epicardium) and VCAM-1 (in the
myocardium) helps to maintain close association of the myocardium and epicardium.
Changing the levels of these two proteins could have detrimental consequences to cellcell (epicardium to myocardium) and cell-ECM (epicardium to subepicardial space)
binding. Increases in the amounts of VCAM-1 protein in the RXRa-/- mouse could affect
the normal stoichiometry of integrin a4NCAM-1 receptor interactions, thus affecting
normal binding of the epicardium and myocardium possibly leading to epicardial
detachment.
Epicardial explants from the RXRa-/- mouse do attach to FN-coated slides,
however, the amount of attachment has not been quantified. In one epicardial explant
experiment using

wr and RXRa-/-, most of the cells of the RXRa-/- explant detached

during the fixation process. However, in another experiment with WT and RXRa-/-
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explants, epicardial cells remained attached during the fixation process. An attachment
assay would need to be devised to further analyze epicardial cell attachment using
RXRa-/- epicardial explants.
Increased VCAM-1 could also bind to different receptors located in the
epicardium and/or myocardium instead of binding to integrin a4. There are no reports in
the literature demonstrating VCAM-1 NCAM-1 binding so the formation of VCAM1NCAM-1 homodimers is unlikely. It is more likely that excess VCAM-1 could bind with
another integrin in the developing heart. Typically, VCAM-1 binds to integrin a4/(31
heterodimers. A study of the chick PE demonstrated that integrins a4, a5, a8, av, (31,
133 and 135 are all expressed in the PE (Pae et aI., 2008). A recent study also found
expression of integrin (32 in the mouse heart, particularly in the epicardium (Oliveira et
aI., 2010). Since integrin (32 is found in the epicardium, it is possible that it could interact
with epicardially-expressed VCAM-1. VCAM-1 on endothelial cell walls was previously
reported to bind to aD(32 integrin on eosinophils (Grayson et aI., 1998) but it is unknown
if this interaction occurs within the heart. Under flow conditions, aDf32 integrin
expressed by lymphoid cells binds to VCAM-1 on endothelial cells at levels that were
similar to binding of a4(31 integrin-expressing inflammatory cells to VCAM-1 on
endothelial cells (Van der Vieren et aI., 1999). This would suggest that VCAM-1/aDf32
integrin binding could be as strong as VCAM-1/a4(31 integrin binding. Another study
found that a9f31 integrin in neutrophils binds to VCAM-1 on endothelial cells for migration
across an endothelial monolayer during the inflammatory process (Taooka et aI., 1999)
suggesting that integrin a4 is not always necessary for VCAM-1 binding. These
alternative interactions of VCAM-1 with integrin subunits other than a4(31 have only been
reported in endothelial and lymphoid cells during inflammation. However, it is possible
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that VCAM-1 interactions with other integrin subunits can occur in the heart since those
subunits are expressed within the heart, particularly in the PE and epicardium.
P13K1Akt

In the developing heart, P13K1Akt can initiate proliferation of cardiomyocytes
(Kang and Sucov, 2005) for ventricular chamber maturation. Binding of VCAM-1 and
integrin a4 can activate P13K1Akt signaling (Figure 7), which can induce myocardial
proliferation in the normal developing heart (Kang and Sucov, 2005). Activation of
P13K1Akt signaling is downstream of integrin a4NCAM-1/FN binding is (Hynes, 2002).
P13K1Akt signaling has also been shown to be activated by an unknown factor secreted
by epicardial cells in response to retinoic acid signaling (Kang and Sucov, 2005).
Altering the normal ligand binding to integrin subunits could modify the downstream
signaling in the developing heart such as P13K1Akt and Erk signaling. The increased FN
present in the RXRa-/- heart (Jenkins et aI., 2005) could also alter the signaling that
occurs from its binding with integrin a4. The RXRu-/- mouse has decreased P13K1Akt
and Erk signaling (Kang and Sucov, 2005), both of which are downstream of integrin
binding.

It is possible that the decreased signaling through those pathways is related to

increased FN binding to integrin a4 or by VCAM-1 binding to another integrin
heterodimer since each one of these interaction can initiate and modify integrinmediated signaling.
A decrease in proliferation was found in the ventricular myocardium of the
RXRa-/- heart as shown by a reduction in mitotic index of myocytes (Kastner et aI.,
1997) and a reduction of PI3K/Akt signaling (Kang and Sucov, 2005). Since the
P13K1Akt pathway is known to induce proliferation and is active in cardiomyocytes, the
reduction in signaling from the P13K1Akt pathway could decrease proliferation of
cardiomyocytes in the RXRa-/- mouse (Kang and Sucov, 2005). This reduction in
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P13K1Akt signaling could be related to the disruption of VCAM-1/integrin a4/FN
stoichiometry because activation of P13K1Akt signaling can occur downstream of integrin
a4 binding. Decreased proliferation due to a reduction of P13K1Akt signaling could lead
to a hypoplastic ventricular myocardium as seen in

RXRa-l- mice (Jenkins et aI., 2005).

Using real time PCR, increased Rac mRNA was observed in RXRa-l- mice
(Brichler, Burton and Kubalak, unpublished). Rac is involved in initiation of migration
downstream of integrin-mediated signaling (Figure 7) and has been found to increase
invasiveness and transformation in cancer (Bosco et aI., 2009). An increase in Rac
would suggest an increase in EMT, but increased EMT is not what is observed in
RXRa-/- mice (Ruiz-Lozano and Kubalak, unpublished). VCAM-1/integrin a4 signaling
can activate Rac1 in mouse and human endothelial cells leading to the production of
reactive oxygen species (ROS) (Cook-Mills, 2002; Deem and Cook-Mills, 2004; van
Wetering et aI., 2003). ROS have been shown to induce dissociation of cell-cell contacts
in retinal pigment epithelial cells through the loss of cadherins on the cell surface without
EMT occurring (Inumaru et aI., 2009). It is possible in RXRa-l- mice that increased
VCAM-1 and increased Rac1 can induce dissociation of cell-cell contacts (possibly
between epicardium and myocardium) without leading to the induction of EMT.
According to a recent study, Foxc proteins are activated by the P13K1Akt pathway
(Hayashi and Kume, 2008). The VCAM-1 promoter contains Fox-binding elements and
the Foxc1 and Foxc2 transcription factors have been shown to activate the VCAM-1
promoter to increase VCAM-1 levels (Kang et aI., 2006). Increased levels of VCAM-1
could, in turn, increase signaling downstream of integrin a4 including the P13K1Akt
signaling (Figure 7). Similar to the RXRa-/- mouse (Jenkins et aI., 2005), the
combination Foxc1+/-/Foxc2-/- mouse has been shown to have a detached epicardium
(Sea and Kume, 2006). In RXRa-/- mice, Foxc1 or Foxc2 expression has not been
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examined. However, it is speculated that the reduction in P13K1Akt signaling in RXRa-/mice (Kang and Sucov, 2005) could cause decreased Foxc1 and/or Foxc2. With
decreased Foxc1 and/or Foxc2, there would be less activation of the VCAM-1 promoter,
resulting in lower levels of VCAM-1. However, in RXRa-/- mice, VCAM-1 is increased
and is likely due to a mechanism independent of P13K1Akt signaling and Foxc1/Foxc2.
In this study, TGF(32 signaling was shown to increase VCAM-1 expression so TGF(32 is
most likely the pathway affecting VCAM-1 expression in RXRa-/- mice.
Effects on EMT
In normal cardiac morphogenesis, VCAM-1 could playa role in regulation of EMT
through signaling by binding to integrin a4 and through cell-cell adhesion. In order for
EMT to occur, there must be some loss of cell adhesion. If VCAM-1 is increased or
expressed in the wrong cells, there could be alterations in cell-cell adhesion and/or
signaling that would impact EMT with increases in cell adhesiveness decreasing EMT.
Recently, VCAM-1 has been shown to negatively impact EMT (Ookic and Dettman,
2006). Treatments with soluble VCAM-1 caused a reduction in EMT by strengthening (3catenin and E-cadherin association between epicardial cells, decreasing basal stress
fibers and promoting formation of apical cortical actin fibers to maintain epicardialepicardial cell attachment (Dokic and Dettman, 2006). The RXRa-/- mouse has been
previously shown to have decreased epicardial EMT (Ruiz-Lozano and Kubalak,
unpublished). VCAM-1, in excess, could decrease epicardial EMT in RXRa-/- mice.
Similarly, other mouse models of aberrant epicardium formation have increased Ecadherin resulting in decreased epicardial EMT including the epicardial-specific Wt1
knockout (Martinez-Estrada et aI., 2010) and the podoplanin knockout (Mahtab et aI.,
2008). Therefore, increased E-cadherin-mediated association between epicardial cells
could decrease epicardial EMT. VCAM-1 was also found to antagonize EMT of
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epicardial cells stimulated by TGFf3 by activating p190RhoGAP thereby altering Rho
activation by TGFf33 (Dokic and Dettman, 2006). Since TGFf3 signaling is known to
increase EMT, the TGFf32 increase observed in RXRu-/- mice would be expected to
increase EMT. However, since EMT is not increased in RXRu-/- mice (Ruiz-Lozano and
Kubalak, unpublished), the increase in VCAM-1 might explain this discrepancy because
VCAM-1 has been shown to reduce TGF(3-induced EMT. A strategy to determine
whether or not VCAM-1 elevation and misexpression in the epicardium alters EMT or
causes epicardial detachment would be to create a mouse model overexpressing
VCAM-1 in the epicardium. This could be done by creating a mouse line using the wt1,
Tbx18 or GATA5 promoter to drive expression of VCAM-1 in the epicardium. The
phenotype of these transgenic embryos could then be analyzed for epicardial bubbling
and alterations in epicardial EMT. Such experiments might provide insight into whether
misexpression of VCAM-1 in the epicardium is responsible for any of the epicardial
phenotype seen in RXRu-/- mice. Conversely, it could be determined if excess VCAM-1
is responsible for epicardial bubbling or decreased EMT by lowering VCAM-1 levels in
the RXRu-/- mouse by creating a compound VCAM-1 +/-RXRu-/- mouse, in which
VCAM-1 levels are genetically reduced.
N-cadherin

In the normal heart, N-cadherin is required for attachment of the epicardium to
the myocardium (Luo et aI., 2006). In this study, our findings indicate there may be a
decrease in N-cadherin in the RXRu-/- mouse (Figure 33). N-cadherin is of interest
because the N-cadherin KO mouse has a detached epicardium (Luo et al., 2006) and Ncadherin is involved in cell-cell attachment through desmosomes and adherens
junctions. Desmosome dysfunction has been previously implicated in skin blistering
diseases (Has and Bruckner-Tuderman, 2006). The phenotype of the skin in blistering
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diseases is quite similar to the phenotype of the bubbled epicardium because the
epithelial cell layer is detached from a loss of normal cell adhesion. Therefore, it is
possible that improper formation of desmosomes is responsible for epicardium
detachment in the RXRa-/- mouse as well as other mouse models with epicardial
bubbling/blistering. Cellular junctions between the epicardium and the myocardium were
less apparent in the RXRa-/- mouse than in the WT, as was seen in TEM analysis
(Figure 21). Future studies examining epicardial/myocardial cellular junctions and
analysis of N-cadherin in the developing heart are needed in order to determine
N-cadherin's role in epicardium attachment.
Decreased N-cadherin has previously been observed in two models of detached
epicardium. N-cadherin is decreased in the Wt1 epicardial-specific knockout (MartinezEstrada et aI., 2010) and the Alk5 epicardial-specific knockout (Sridurongrit et aI., 2008),
both of which have a decrease in epicardial EMT and a detached epicardium. The
detachment of the epicardium in the RXRa-/- mouse may be due to a decrease in Ncadherin and not necessarily to misregulation of VCAM-1, whereas an increase in
VCAM-1 may be contribute more to the decrease in EMT and EPDC formation.
Therefore, the role of VCAM-1 in the normal heart following the formation of the
epicardium could be in regulating epicardial EMT to form EPDCs that contribute cells
and signals for normal cardiac morphogenesis.
TGFB2 signaling

TGFf32 signaling is known to be important for cardiac morphogenesis especially
in activating EMT and in apoptosis in the endocardial cushions (Camenisch et aI., 2002;
Kubalak et aI., 2002). TGF(32-/- mouse embryos have a multitude of cardiac defects
including ventricular and outflow tract defects, hypoplastic ascending aorta, double outlet
right ventricle and dual inlet left ventricle (Sanford et aI., 1997), indicating the importance
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of TGFf32 signaling to the developing heart. An increase in TGFf32 protein and mRNA
was seen in the RXRa-/- heart in previous studies (Kubalak et aI., 2002; Jenkins and
Kubalak, unpublished) as well as this current study (Figures 26 and 33). TGFf32 is
known to regulate the transcription of several genes through its role as a growth factor
and is expressed in the epicardium. Because of misexpression of VCAM-1 in the
RXRa-/- epicardium and increased TGFf32 in the heart of the RXRa-/- mouse occur
during the same developmental timeframe, this study focused on whether TGFf32 could
regulate the expression of VCAM-1 in epicardial cells.
Both RXRa and Smad4 were shown to bind to the VCAM-1 promoter by using
ChiP analysis (Figure 35). Binding of Smad4 to the promoter might indicate that any
member of the TGFf3 and BMP family is capable of regulating the VCAM-1 promoter.
TGFf32 was shown to regulate VCAM-1 expression in epicardial explants (Figure 38),
whole embryo culture (Figures 36 and 37) and VCAM-1 promoter luciferase assays
(Figures 39 and 40). However, the effect of other TGFf3 family members on VCAM-1
expression is not known. Further analysis of the other TGFf3 family members would be
necessary to determine if TGF(32 is the only member regulating the VCAM-1 promoter.
In the future, the effect of TGF(31, TGFf33, (because of its overlapped expression with
TGFf32 (Molin et aI., 2003» BMP2 and BMP4 (because of expression in the PE (Kruithof
et aI., 2006; Schlueter et aI., 2006» on VCAM-1 expression needs to be defined.
Using REC cells transfected with the VC1889 VCAM-1 promoter luciferase
plasmid, TGF(32 was shown to activate transcription from the VCAM-1 promoter. There
are numerous putative SBEs present on the VCAM-1 promoter so promoter deletion
constructs are needed to determine which possible SBEs are involved (due to their
localization in the deleted region). Following promoter deletion studies, mutational
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analysis of possible SBEs could be used to determine which SBEs are involved in the
regulation of VCAM-1 transcription.
Retinoic Acid Signaling
A proper balance of retinoid signaling is required for cardiac mophogenesis to
occur normally with too much or too little retinoid signaling resulting in heart defects as
has been demonstrated previously with the VAD rat model and in gestational exposure
to Accutane (isotretinoin) (de la Cruz et aI., 1984; Wilson and Warkany, 1949).
Retinoid consensus binding sites were found on the VCAM-1 promoter (Figure 14)
suggesting that VCAM-1 could be regulated by retinoid signaling. However, treatment
with 9-cisRA had no effect on the expression of VCAM-1 in epicardial explants or in
embryos in WECo Furthermore, 9-cisRA did not regulate the VCAM-1 promoter, in cells
transfected with the VC1889 luciferase expression plasmid. Despite these findings, it is
possible that another retinoid (such as all-transRA to activate RARs) or ligand that
activates a retinoid receptor-binding partner (such as Vitamin D for the Vitamin D
receptor) may playa role in regulating VCAM-1. It is also possible that the retinoid
consensus elements found on the VCAM-1 promoter are not functional retinoid binding
elements so, therefore, would have no effect on VCAM-1 activation. However, since
RXRa bound to the VCAM-1 promoter, it is possible that RXRa acts as a heterodimer
with another nuclear receptor. Therefore, in order for RXRa to have an effect on the
VCAM-1 promoter, the heterodimer partner of RXRa would also need to be activated by
ligand binding.
In the heart, RXRa may have more of a direct effect on TGF(32 signaling than
VCAM-1 since 9-cisRA treatment did not activate the VCAM-1 promoter. Previously it
has been proposed that RXRa regulates activation of Smad2 since loss of RXRa (in the
RXRa-/- mouse) or dual treatment with TGF(32 and 9-cisRA (in NIH3T3 cells) will
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increase Smad2 phosphorylation (Hoover et al., 2008b). Although Smad
phosphorylation was increased, nuclear localization of pSmad was decreased in both
the RXRa-/- mouse and with TGFf32/9-cisRA treatments (Hoover et aI., 2008b). It was
hypothesized that RXRa was acting as a nuclear shuttle for pSmad2 when it is located
on the nuclear membrane (Hoover et aI., 2008b). In the RXRa-/- mouse or with 9-cisRA
treatment when RXRa is not present at the nuclear membrane, there is a decrease in
pSmad2 in the nucleus, indicating an uncoupling of TGFf32 signaling (Hoover et aI.,
2008b). The increase in TGFf32 seen in the RXRa-/- mouse could be a compensatory
mechanism since pSmad2 may be unable to get into the nucleus to signal (Hoover et aI.,
2008b). In response to the lack of TGFf32 signaling, the cell could increase TGFf32
levels (Hoover et aI., 2008b). However, the uncoupling hypothesis would not explain the
increase in VCAM-1 since in this current study it was found that TGFf32 signaling can
increase VCAM-1 expression. Importantly, the uncoupling of TGFf32 signaling in the
RXRa-/- mouse is not seen in the entire heart. For example, decreased nuclear
localization of phosphorylated Smad2 was seen in the cushions of the heart but was not
observed in the epicardium or myocardium (Hoover and Kubalak, unpublished). TGFf32
could also activate p38 (part of MAPK signaling) to activate transcription of VCAM-1.
TGFf32 has been previously shown to cause phosphorylation of p38 by activation of
TGFr3 associated kinase (TAK1) (Yamashita et aI., 2008). Several studies have shown
that induction of VCAM-1 expression is dependent on activation of p38. Inhibition of p38
has been shown to suppress VCAM-1 expression induced by tumor necrosis factor a
(TNFa) (Ho et aI., 2008), cadmium (Park et aI., 2009), interleukin f3 (lL-f3) (Wang et aI.,
2005) and C reactive protein (CRP) (Kawanami et aI., 2006). Thus, the increased
VCAM-1 may be independent of Smad-binding and instead a response to p38 activation
by TGFf32, which would still occur even if Smad2 is uncoupled.
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Conclusion
From this study, it is proposed that VCAM-1 is playing roles in attachment,
signaling and regulation of epicardial EMT in the developing heart, each of which will be
discussed in this section. First, VCAM-1 is involved in epicardial cell attachment to the
myocardium. VCAM-1 is necessary in the initial attachment of the PE cells to the
myocardium to form the epicardium (Kwee et aI., 1995; Yang et aI., 1995) but may not
playa role in the later attachment (starting at E11.5) to maintain epicardial adhesion to
the myocardium. VCAM-1 and integrin a4 are essential for the initial attachment of PE
buds to the myocardium as was demonstrated by both the integrin a4 and VCAM-1 KO
mice, both of which fail to form an epicardium (Kwee et aI., 1995; Yang et aI., 1995). In
both the VCAM-1 and integrin a4 knockout mice, PE buds form and migrate to the
myocardium but fail to adhere to the myocardium. Therefore, VCAM-1 and integrin a4
are not required for PE bud formation (Kwee et aI., 1995; Yang et aI., 1995). In the
RXRa-/- mouse, delay in epicardium formation is likely due to an increase in VCAM-1
expression, resulting in increased adhesiveness of PE cells within the PE. Increased PE
cell adhesion could prevent or slow the formation of PE buds resulting in a delay of
epicardium formation. Furthermore, findings from a previous study demonstrating
decreased cell outgrowth in PE explants could be indicative of increased cell adhesion
(Jenkins and Kubalak, unpublished).
As for the epicardial cell detachment in the RXRa-/- mouse, N-cadherin is likely
responsible for maintenance of epicardial cell adhesion following epicardium formation
(Figure 41, 1). The N-cadherin KO mouse has a detached epicardium and N-cadherin is
expressed in both the epicardium and myocardium (Luo et aI., 2006). Data from this
study suggest that N-cadherin levels are decreased, which would decrease epicardial
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Figure 41: Diagrammatic representation of the current working hypothesis. See text for
further explanation. N-cadherin is necessary for binding of the epicardium to the
myocardium (1). Increased VCAM-1 levels strengthen epicardial-epicardial cell adhesion
through increasing interactions of ~-catenin and E-cadherin between epicardial cells (2).
Binding of VCAM-1 to integrin a4~ 1 can activate signaling through the P13K1Akt and Erk
signaling cascades (3). Increased FN could increase signaling downstream of integrin
a4~1 (4). V, VCAM-1; N, N-cadherin; a4, integrin a4; ~1, integrin ~1; ~, ~-catenin; E, Eo.
cadherin
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cell adhesion to the myocardium. Further analysis of N-cadherin in the RXRa-/- mouse
would need to be performed to support this conclusion.
It is proposed that VCAM-1 plays a role in regulating epicardial EMT either
through cell adhesion of epicardial cells or through signaling with integrin a4.
Previously, it has been demonstrated· that soluble VCAM-1 can decrease epicardial cell
EMT by strengthening epicardial cell-cell association with f3-catenin and E-cadherin on
the cell surface (Dokic and Dettman, 2006). Decreased epicardial EMT is observed in
the RXRa-/- mouse (Ruiz-Lozano and Kubalak, unpublished) as well as increased
VCAM-1. If the increased VCAM-1 in the RXRa-/- mouse heart is increasing epicardial
cell-cell association with f3-catenin and E-cadherin, then there could be increased
epicardial cell-cell adhesion and a decrease in EMT through cell-cell binding by Ecadherin (Figure 41, 2). Decreased epicardial EMT could contribute to some of the
cardiac phenotype of the RXRa-/- mouse, including the hypoplastic ventricular
myocardium which can occur as a result of fewer EPDCs (Jenkins et aI., 2005).
Finally, it is suggested that VCAM-1 is playing a role in signaling in the
developing heart (Figure 41,3). By binding with integrin a4, VCAM-1 can initiate several
possible signaling cascades (Figure 7). P13K1Akt and Erk signaling are activated
downstream of VCAM-1/integrin a4 binding (Figure 7). Both P13K1Akt and Erk signaling
are decreased in the RXRa-/- mouse (Kang and Sucov, 2005). Both P13K1Akt and Erk
signaling can initiate proliferation of myocytes and decreased P13K1Akt or Erk signaling
could decrease myocyte proliferation (Kang and Sucov, 2005). Increased P13K1Akt or
Erk signaling might be expected if there is increased VCAM-1/integrin a4 binding.
However, this is not seen in the RXRu-/- mouse (Ruiz-Lozano and Kubalak,
unpublished), so the decrease in P13K1Akt or Erk signaling may be unrelated to VCAM1/integrin a4 signaling or may reflect a decrease in interactions between a4 integrin and
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VCAM-1. Alternatively, the loss of RXRa in the RXRa-/- mouse could also affect
signaling through the loss of gene transcription or through its role as a nuclear shuttle.
The decrease in P13K1Akt could be directly related to loss of RXRa. Since there is also
increased FN in the RXRa-/- heart (Jenkins et aI., 2005), an increase in FN binding to
integrin a4 could also alter downstream signaling, including P13K1Akt and Erk signaling
(Figure 41, 4). However, since the FN network is disorganized, signaling from
FN/integrin a4 binding could be adversely affected. Thus, increased FN may not
increase integrin a4-mediated signaling in the developing heart due the disorganization
in the FN network in the subepicardial space.
From this study, increased VCAM-1 was found in the RXRa-/- mouse heart and
can be regulated by

TGF~2

signaling. Several roles of VCAM-1 were proposed in the

developing heart. Our study and those of others illustrate that cell adhesion molecules,
particularly VCAM-1, playa significant role in cell adhesion as well as in signaling and
EMT during heart development and demonstrates the importance of correct cell-type
specific expression of cell adhesion molecules during the formation of the heart.
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